[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 53 of about 53
1. Beer S, Bellovin DI, Lee JS, Komatsubara K, Wang LS, Koh H, Börner K, Storm TA, Davis CR, Kay MA, Felsher DW, Grimm D: Low-level shRNA cytotoxicity can contribute to MYC-induced hepatocellular carcinoma in adult mice. Mol Ther; 2010 Jan;18(1):161-70
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Low-level shRNA cytotoxicity can contribute to MYC-induced hepatocellular carcinoma in adult mice.
  • As expected, the shRNAs silenced hepatic p53 and accelerated liver tumorigenesis when MYC was concurrently expressed.
  • In MYC-expressing transgenic mice, the marginal shRNA-induced liver injury sufficed to further stimulate hepatocellular division that was in turn associated with markedly increased expression of the mitotic cyclin B1.
  • Hence, even at low doses, shRNAs can cause low-level hepatoxicity that can facilitate the ability of the MYC oncogene to induce liver tumorigenesis.
  • [MeSH-major] Carcinoma, Hepatocellular / chemically induced. Genes, myc / physiology. Liver Neoplasms, Experimental / chemically induced. RNA, Small Interfering / adverse effects

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Hepatology. 2001 Mar;33(3):738-50 [11230756.001]
  • [Cites] Annu Rev Cell Dev Biol. 2000;16:653-99 [11031250.001]
  • [Cites] Gene Ther. 2001 Aug;8(16):1248-54 [11509958.001]
  • [Cites] Cancer Res. 2001 Sep 1;61(17):6487-93 [11522645.001]
  • [Cites] Adv Cancer Res. 2002;84:81-154 [11885563.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Apr 30;99(9):6274-9 [11983916.001]
  • [Cites] Semin Liver Dis. 2002;22(2):137-44 [12016545.001]
  • [Cites] Nat Genet. 2002 Aug;31(4):339-46 [12149612.001]
  • [Cites] Nat Rev Cancer. 2002 Oct;2(10):764-76 [12360279.001]
  • [Cites] Nature. 2003 Jan 16;421(6920):290-4 [12529648.001]
  • [Cites] Curr Gene Ther. 2003 Aug;3(4):281-304 [12871018.001]
  • [Cites] Front Biosci. 1998 Feb 15;3:d250-68 [9468463.001]
  • [Cites] Nature. 2004 Oct 28;431(7012):1112-7 [15475948.001]
  • [Cites] Pharmacol Ther. 1989;43(1):139-54 [2675128.001]
  • [Cites] Cell. 1989 Dec 22;59(6):1145-56 [2598264.001]
  • [Cites] Cancer Res. 1990 Jun 1;50(11):3400-7 [1692259.001]
  • [Cites] Cell. 1993 Nov 5;75(3):451-62 [8106172.001]
  • [Cites] Am J Pathol. 1994 Nov;145(5):1237-45 [7977654.001]
  • [Cites] Hepatology. 1995 Oct;22(4 Pt 1):1316-25 [7557887.001]
  • [Cites] J Virol. 1996 Jul;70(7):4646-54 [8676491.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Oct 1;93(20):10933-8 [8855286.001]
  • [Cites] J Biol Chem. 1998 Jun 19;273(25):15639-45 [9624157.001]
  • [Cites] Mol Cell Biol. 1999 Jan;19(1):1-11 [9858526.001]
  • [Cites] Carcinogenesis. 1999 Jan;20(1):41-9 [9934848.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Mar 30;96(7):3940-4 [10097142.001]
  • [Cites] Oncogene. 1999 May 13;18(19):2934-41 [10378690.001]
  • [Cites] Mol Cell. 1999 Aug;4(2):199-207 [10488335.001]
  • [Cites] Semin Liver Dis. 1999;19(3):243-52 [10518304.001]
  • [Cites] PLoS Biol. 2004 Nov;2(11):e332 [15455033.001]
  • [Cites] J Virol. 2005 Jan;79(1):214-24 [15596817.001]
  • [Cites] Methods Enzymol. 2005;392:381-405 [15644194.001]
  • [Cites] Toxicol Pathol. 2005;33(1):181-4 [15805070.001]
  • [Cites] Cancer Biol Ther. 2004 Oct;3(10):942-4 [15611633.001]
  • [Cites] Gene Ther. 2006 Mar;13(6):563-75 [16453009.001]
  • [Cites] Nature. 2006 May 25;441(7092):537-41 [16724069.001]
  • [Cites] Cancer Res. 2006 Aug 1;66(15):7390-4 [16885332.001]
  • [Cites] Nat Methods. 2006 Sep;3(9):689-95 [16929313.001]
  • [Cites] Genome Biol. 2006;7(8):231 [16942630.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Sep 18;104(38):14917-22 [17848523.001]
  • [Cites] Nat Genet. 2008 Jan;40(1):43-50 [18066065.001]
  • [Cites] J Virol. 2008 Jun;82(12):5887-911 [18400866.001]
  • [Cites] J Biol Chem. 2008 Jul 11;283(28):19184-91 [18456653.001]
  • [Cites] J Biol Chem. 2008 Aug 8;283(32):22186-92 [18524776.001]
  • [Cites] Mol Ther. 2008 Sep;16(9):1630-6 [18665161.001]
  • [Cites] Nat Rev Mol Cell Biol. 2008 Oct;9(10):810-5 [18698328.001]
  • [Cites] Cell. 2009 Jun 12;137(6):1005-17 [19524505.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Feb 29;97(5):2229-34 [10688915.001]
  • [Cites] Annu Rev Pharmacol Toxicol. 2000;40:42-65 [10836127.001]
  • [Cites] Mol Carcinog. 2000 Jul;28(3):168-73 [10942533.001]
  • [Cites] J Virol. 2001 Aug;75(15):6969-76 [11435577.001]
  • (PMID = 19844192.001).
  • [ISSN] 1525-0024
  • [Journal-full-title] Molecular therapy : the journal of the American Society of Gene Therapy
  • [ISO-abbreviation] Mol. Ther.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P01-CA03423; United States / NCI NIH HHS / CA / R01-CA89305; United States / NIDDK NIH HHS / DK / DK078424; United States / NCI NIH HHS / CA / F32-CA132312; United States / NCI NIH HHS / CA / R01 CA089305; United States / NCI NIH HHS / CA / F32 CA132312; United States / NIDDK NIH HHS / DK / R01 DK078424; United States / NCI NIH HHS / CA / P50-CA114747; United States / NCI NIH HHS / CA / R01 CA105102; United States / NCI NIH HHS / CA / R01-CA105102; United States / NCI NIH HHS / CA / P50 CA114747
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / RNA, Small Interfering
  • [Other-IDs] NLM/ PMC2839214
  •  go-up   go-down


2. Soon JL, Jeyaraj PR, Agasthian T: Thoracic complications of radiofrequency ablation of recurrent hepatoma. Ann Acad Med Singapore; 2008 Jan;37(1):75-6
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Thoracic complications of radiofrequency ablation of recurrent hepatoma.
  • INTRODUCTION: Radiofrequency ablation (RFA) for unresectable primary or secondary hepatic malignancies have gained widespread availability and acceptance over the past 5 years.
  • CLINICAL PICTURE: We report a patient with symptomatic right pleural effusion due to a diaphragmatic fistula and another with biliptysis post-RFA, for recurrent hepatoma.
  • [MeSH-major] Carcinoma, Hepatocellular / surgery. Catheter Ablation / adverse effects. Diaphragm / physiopathology. Liver Neoplasms / surgery. Neoplasm Recurrence, Local / surgery
  • [MeSH-minor] Adult. Aged. Fistula / etiology. Humans. Male. Pleural Effusion / etiology

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18265903.001).
  • [ISSN] 0304-4602
  • [Journal-full-title] Annals of the Academy of Medicine, Singapore
  • [ISO-abbreviation] Ann. Acad. Med. Singap.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Singapore
  •  go-up   go-down


3. Olsavsky KM, Page JL, Johnson MC, Zarbl H, Strom SC, Omiecinski CJ: Gene expression profiling and differentiation assessment in primary human hepatocyte cultures, established hepatoma cell lines, and human liver tissues. Toxicol Appl Pharmacol; 2007 Jul 1;222(1):42-56
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gene expression profiling and differentiation assessment in primary human hepatocyte cultures, established hepatoma cell lines, and human liver tissues.
  • Frequently, primary hepatocytes are used as an in vitro model for the liver in vivo.
  • In this study, we characterized the differentiation character of primary human hepatocytes cultured using a highly defined, serum-free two-dimensional sandwich system, one that configures hepatocytes with collagen I as the substratum together with a dilute extracellular matrix (Matrigeltrade mark) overlay combined with a defined serum-free medium containing nanomolar levels of dexamethasone.
  • Whole genome expression profiling enabled direct comparison of liver tissues to hepatocytes and to the hepatoma-derived cell lines, HepG2 and Huh7.
  • The robustness of the primary hepatocyte cultures was reflected by the extent of unchanged expression character when compared directly to liver, with more than 77% of the probe sets unchanged in each of the over-represented categories, representing such genes as C/EBPalpha, HNF4alpha, CYP2D6, and ABCB1.
  • In contrast, HepG2 and Huh7 cells were unchanged from the liver tissues for fewer than 48% and 55% of these probe sets, respectively.
  • Further, hierarchical clustering of the hepatocytes, but not the cell lines, shifted from donor-specific to treatment-specific when the probe sets were filtered to focus on phenobarbital-inducible genes, indicative of the highly differentiated nature of the hepatocytes when cultured in a highly defined two-dimensional sandwich system.

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. Phenobarbital .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nucleic Acids Res. 2006 Jul 1;34(Web Server issue):W645-50 [16912992.001]
  • [Cites] Toxicol In Vitro. 2002 Feb;16(1):89-99 [11812644.001]
  • [Cites] Clin Pharmacol Ther. 2000 Oct;68(4):356-66 [11061575.001]
  • [Cites] Biochem Pharmacol. 2001 May 15;61(10):1293-303 [11322933.001]
  • [Cites] Bioinformatics. 2001 Jun;17(6):509-19 [11395427.001]
  • [Cites] Toxicol Sci. 2002 Jun;67(2):219-31 [12011481.001]
  • [Cites] Xenobiotica. 2002 Jun;32(6):505-20 [12160483.001]
  • [Cites] Science. 2002 Oct 11;298(5592):422-4 [12376703.001]
  • [Cites] Toxicol Sci. 2003 Jun;73(2):386-402 [12657743.001]
  • [Cites] Mol Endocrinol. 2003 Jul;17(7):1268-82 [12663745.001]
  • [Cites] Drug Metab Dispos. 2003 Aug;31(8):1035-42 [12867492.001]
  • [Cites] Toxicol Sci. 2003 Sep;75(1):208-22 [12832660.001]
  • [Cites] Genome Res. 2003 Sep;13(9):2129-41 [12952881.001]
  • [Cites] Exp Cell Res. 2004 Jan 15;292(2):252-64 [14697333.001]
  • [Cites] Mol Pharmacol. 2004 Mar;65(3):550-7 [14978233.001]
  • [Cites] Genomics. 2004 Apr;83(4):541-9 [15028276.001]
  • [Cites] J Biol Chem. 2004 May 21;279(21):22250-7 [15004017.001]
  • [Cites] Pharm Res. 2004 Jul;21(7):1294-302 [15290872.001]
  • [Cites] Proc Natl Acad Sci U S A. 1988 Apr;85(7):2161-5 [3353374.001]
  • [Cites] Arch Biochem Biophys. 1993 Feb 15;301(1):103-13 [8442654.001]
  • [Cites] Biomaterials. 1996 Feb;17(3):373-85 [8745335.001]
  • [Cites] Methods Enzymol. 1996;272:388-401 [8791798.001]
  • [Cites] Toxicol Pathol. 1996 Jan-Feb;24(1):48-57 [8839280.001]
  • [Cites] Arch Biochem Biophys. 1997 Jan 15;337(2):275-83 [9016823.001]
  • [Cites] Biochem Pharmacol. 1997 Oct 1;54(7):761-72 [9353130.001]
  • [Cites] Drug Metab Dispos. 1999 Jun;27(6):637-44 [10348791.001]
  • [Cites] Drug Metab Dispos. 1999 Aug;27(8):887-94 [10421615.001]
  • [Cites] Drug Metab Dispos. 1999 Aug;27(8):909-15 [10421618.001]
  • [Cites] J Biol Chem. 2004 Nov 19;279(47):49517-22 [15358766.001]
  • [Cites] Drug Metab Dispos. 2005 Mar;33(3):388-94 [15608134.001]
  • [Cites] Toxicol Sci. 2005 Jun;85(2):927-34 [15772367.001]
  • [Cites] BMC Genomics. 2005;6:59 [15854232.001]
  • [Cites] Reprod Toxicol. 2005 Sep-Oct;20(3):433-40 [15964738.001]
  • [Cites] Toxicology. 2006 Feb 1;218(2-3):205-15 [16337326.001]
  • [Cites] BMC Bioinformatics. 2006;7:49 [16448562.001]
  • [Cites] Mol Pharmacol. 2002 Jan;61(1):1-6 [11752199.001]
  • [Cites] BMC Bioinformatics. 2006;7:359 [16872483.001]
  • (PMID = 17512962.001).
  • [ISSN] 0041-008X
  • [Journal-full-title] Toxicology and applied pharmacology
  • [ISO-abbreviation] Toxicol. Appl. Pharmacol.
  • [Language] ENG
  • [Grant] United States / NIEHS NIH HHS / ES / ES011387-02; United States / NIEHS NIH HHS / ES / U19 ES011387-05; United States / NIGMS NIH HHS / GM / R01 GM066411-03; United States / NIGMS NIH HHS / GM / R01 GM066411; United States / NIEHS NIH HHS / ES / ES011387-04; United States / NIGMS NIH HHS / GM / GM066411-01; United States / NIEHS NIH HHS / ES / U19 ES011387-05S1; United States / NIGMS NIH HHS / GM / GM066411; United States / NIEHS NIH HHS / ES / P30 ES005022; United States / NIEHS NIH HHS / ES / ES011387-01; United States / NIEHS NIH HHS / ES / U19 ES011387; United States / NIGMS NIH HHS / GM / R01 GM066411-01; United States / NIGMS NIH HHS / GM / GM066411-04; United States / NIEHS NIH HHS / ES / U19 ES011387-04; United States / NIEHS NIH HHS / ES / ES011387-03; United States / NIGMS NIH HHS / GM / R01 GM066411-02; United States / NIEHS NIH HHS / ES / U19 ES11387; United States / NIGMS NIH HHS / GM / GM066411-02; United States / NIEHS NIH HHS / ES / ES011387-05S1; United States / NIEHS NIH HHS / ES / U19 ES011387-01; United States / NIEHS NIH HHS / ES / U19 ES011387-03; United States / NIEHS NIH HHS / ES / ES011387-05; United States / NIGMS NIH HHS / GM / GM066411-03; United States / NIEHS NIH HHS / ES / U19 ES011387-02; United States / NIGMS NIH HHS / GM / R01 GM066411-04
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Differentiation; 0 / Biomarkers; 63231-63-0 / RNA; YQE403BP4D / Phenobarbital
  • [Other-IDs] NLM/ NIHMS243113; NLM/ PMC2974173
  •  go-up   go-down


Advertisement
4. Salguero FJ, Richard A, Gough J, Long A, Weyer U, Cooley WA, Chambers MA, Lesellier S: Pelioid hepatocellular carcinoma in an adult Eurasian badger (Meles meles). J Comp Pathol; 2010 Feb-Apr;142(2-3):208-12
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pelioid hepatocellular carcinoma in an adult Eurasian badger (Meles meles).
  • A mass was identified within the left lateral lobe of the liver of a 10-year-old Eurasian badger (Meles meles).
  • The histological appearance was consistent with hepatocellular carcinoma (HCC).
  • [MeSH-major] Carcinoma, Hepatocellular / veterinary. Liver / pathology. Liver Neoplasms / veterinary. Mustelidae

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Crown Copyright 2009. Published by Elsevier Ltd. All rights reserved.
  • (PMID = 19683720.001).
  • [ISSN] 1532-3129
  • [Journal-full-title] Journal of comparative pathology
  • [ISO-abbreviation] J. Comp. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


5. El-Tahir HM, Abouzied MM, Gallitzendoerfer R, Gieselmann V, Franken S: Hepatoma-derived growth factor-related protein-3 interacts with microtubules and promotes neurite outgrowth in mouse cortical neurons. J Biol Chem; 2009 Apr 24;284(17):11637-51
Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hepatoma-derived growth factor-related protein-3 interacts with microtubules and promotes neurite outgrowth in mouse cortical neurons.
  • Hepatoma-derived growth factor-related proteins (HRP) comprise a family of 6 members, which the biological functions are still largely unclear.
  • Upon maturation HRP-3 relocalizes continuously to the nuclei and in the majority of neurons of adult mice it is located exclusively in the nucleus.
  • This redistribution from neurites to nuclei is also found in embryonic cortical neurons maturing in cell culture.
  • We show that HRP-3 is necessary for proper neurite outgrowth in primary cortical neurons.
  • [MeSH-minor] Amino Acid Sequence. Animals. Brain / embryology. Cell Proliferation. Cytoskeleton / metabolism. Dimerization. Mice. Models, Biological. Molecular Sequence Data. Tubulin / chemistry

  • Gene Ontology. gene/protein/disease-specific - Gene Ontology annotations from this paper .
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Biol Chem. 2001 Oct 5;276(40):37564-8 [11481329.001]
  • [Cites] J Biol Chem. 1999 Mar 19;274(12):8029-38 [10075702.001]
  • [Cites] Nat Cell Biol. 2002 Aug;4(8):583-91 [12134159.001]
  • [Cites] Biochem J. 2002 Sep 1;366(Pt 2):491-500 [12006088.001]
  • [Cites] Cell Mol Life Sci. 2003 Feb;60(2):413-21 [12678504.001]
  • [Cites] Methods Cell Biol. 2003;71:287-304 [12884695.001]
  • [Cites] J Biol Chem. 2003 Sep 5;278(36):34691-9 [12807913.001]
  • [Cites] Cancer. 2003 Oct 1;98(7):1444-56 [14508832.001]
  • [Cites] Int Rev Cytol. 2003;227:183-219 [14518552.001]
  • [Cites] Neuron. 2003 Oct 9;40(2):209-27 [14556705.001]
  • [Cites] J Neurobiol. 2004 Jan;58(1):18-33 [14598367.001]
  • [Cites] J Neurobiol. 2004 Jan;58(1):34-47 [14598368.001]
  • [Cites] Biochem J. 2004 Feb 15;378(Pt 1):169-76 [14572309.001]
  • [Cites] J Biol Chem. 2004 Jun 25;279(26):27320-6 [15140875.001]
  • [Cites] J Biol Chem. 2004 Jul 16;279(29):30850-5 [15136563.001]
  • [Cites] J Biol Chem. 2004 Nov 26;279(48):50176-80 [15466863.001]
  • [Cites] FEBS J. 2005 Feb;272(3):822-31 [15670162.001]
  • [Cites] Clin Cancer Res. 2006 Jan 1;12(1):117-22 [16397032.001]
  • [Cites] Protein Sci. 2006 Feb;15(2):314-23 [16384999.001]
  • [Cites] Ann Surg Oncol. 2006 Feb;13(2):159-67 [16411141.001]
  • [Cites] BMC Neurosci. 2006;7:6 [16430771.001]
  • [Cites] Nucleic Acids Res. 2006;34(5):1653-65 [16549878.001]
  • [Cites] J Mol Biol. 2006 Jul 21;360(4):760-73 [16793062.001]
  • [Cites] Philos Trans R Soc Lond B Biol Sci. 2006 Sep 29;361(1473):1575-92 [16939976.001]
  • [Cites] J Neurochem. 2006 Oct;99(1):70-83 [16987236.001]
  • [Cites] Curr Opin Cell Biol. 2006 Dec;18(6):609-15 [16934447.001]
  • [Cites] J Mol Biol. 2007 Mar 23;367(2):456-72 [17270212.001]
  • [Cites] Genes Dev. 2007 Mar 1;21(5):483-96 [17344411.001]
  • [Cites] BMC Mol Biol. 2007;8:101 [17974029.001]
  • [Cites] Blood. 2008 Feb 1;111(3):1617-24 [18024791.001]
  • [Cites] Cell. 2009 Feb 6;136(3):551-64 [19185337.001]
  • [Cites] J Mol Biol. 2009 Mar 6;386(4):938-50 [19162039.001]
  • [Cites] Biochem Biophys Res Commun. 1999 Dec 9;266(1):81-7 [10581169.001]
  • [Cites] J Biol Chem. 2000 Jun 16;275(24):17917-20 [10770920.001]
  • [Cites] Invest Ophthalmol Vis Sci. 2000 Aug;41(9):2648-57 [10937578.001]
  • [Cites] Nat Neurosci. 2001 Aug;4(8):781-2 [11477421.001]
  • [Cites] J Mol Biol. 2004 Nov 5;343(5):1365-77 [15491618.001]
  • [Cites] Anal Biochem. 1988 Nov 15;175(1):91-5 [3245580.001]
  • [Cites] Int J Dev Biol. 1994 Mar;38(1):13-25 [8074993.001]
  • [Cites] Nature. 1996 Oct 10;383(6600):550-3 [8849730.001]
  • [Cites] Biochem Biophys Res Commun. 1997 Sep 8;238(1):26-32 [9299445.001]
  • [Cites] J Biol Chem. 1997 Dec 26;272(52):33118-24 [9407097.001]
  • [Cites] J Biol Chem. 2002 Mar 22;277(12):10315-22 [11751870.001]
  • (PMID = 19237540.001).
  • [ISSN] 0021-9258
  • [Journal-full-title] The Journal of biological chemistry
  • [ISO-abbreviation] J. Biol. Chem.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Hdgfrp3 protein, mouse; 0 / Nuclear Proteins; 0 / Tubulin
  • [Other-IDs] NLM/ PMC2670168
  •  go-up   go-down


6. Tsai S, Gurakar A, Anders R, Lam-Himlin D, Boitnott J, Pawlik TM: Management of large hepatocellular carcinoma in adult patients with Alagille syndrome: a case report and review of literature. Dig Dis Sci; 2010 Nov;55(11):3052-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Management of large hepatocellular carcinoma in adult patients with Alagille syndrome: a case report and review of literature.
  • BACKGROUND: Alagille syndrome is a multi-system developmental disorder associated with paucity of interlobular bile ducts and cholestasis, rarely associated with hepatocellular carcinoma.
  • As such, we herein review the modern management of a large hepatocellular carcinoma in an adult patient with Alagille syndrome and review the literature of adult Alagille patients with hepatocellular carcinoma.
  • CASE PRESENTATION: A 29-year-old woman with a history of Alagille syndrome was referred with biopsy-proven 12 × 8 cm hepatocellular carcinoma replacing her right liver.
  • Biopsy of the contralateral liver demonstrated findings consistent with Alagille syndrome, but no underlying cirrhosis.
  • CT volumetrics demonstrated a future liver remnant of 40%.
  • [MeSH-major] Alagille Syndrome / epidemiology. Carcinoma, Hepatocellular / epidemiology. Carcinoma, Hepatocellular / surgery. Hepatectomy / methods. Liver Neoplasms / epidemiology. Liver Neoplasms / surgery
  • [MeSH-minor] Adult. Comorbidity. Female. Humans. Magnetic Resonance Imaging. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Alagille Syndrome.
  • Genetic Alliance. consumer health - Hepatocellular carcinoma, adult.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Med Pediatr Oncol. 1992;20(1):78-83 [1309208.001]
  • [Cites] Am J Gastroenterol. 1993 Sep;88(9):1446-9 [8395765.001]
  • [Cites] J Med Genet. 2003 Dec;40(12 ):891-5 [14684686.001]
  • [Cites] Dig Dis Sci. 1986 Apr;31(4):438-42 [3007058.001]
  • [Cites] Arch Surg. 1993 Mar;128(3):337-9 [8442692.001]
  • [Cites] World J Surg. 2008 Sep;32(9):2070-6 [18452024.001]
  • [Cites] J Am Coll Surg. 2001 Jul;193(1):109-11 [11442247.001]
  • [Cites] Anesth Analg. 1999 Nov;89(5):1137-42 [10553824.001]
  • [Cites] Hepatology. 1982 Jul-Aug;2(4):467-74 [7095746.001]
  • [Cites] Leber Magen Darm. 1996 May;26(3):157-8, 161-3 [8709830.001]
  • [Cites] J Pediatr Gastroenterol Nutr. 1989 Jan;8(1):26-30 [2543804.001]
  • [Cites] Clin Nucl Med. 1988 Dec;13(12 ):920-1 [2854508.001]
  • [Cites] Br J Surg. 2001 Feb;88(2):165-75 [11167863.001]
  • [Cites] Transplantation. 2001 Jul 27;72(2):345-7 [11477367.001]
  • [Cites] Hepatology. 1999 Mar;29(3):822-9 [10051485.001]
  • [Cites] World J Gastroenterol. 2003 Dec;9(12):2737-41 [14669324.001]
  • [Cites] Surgery. 1991 Aug;110(2):176-82; discussion 182-3 [1858028.001]
  • [Cites] Catheter Cardiovasc Interv. 2004 May;62(1):71-7 [15103608.001]
  • [Cites] Gastroenterology. 1990 Nov;99(5):1514-6 [2170223.001]
  • [Cites] N Engl J Med. 2004 Sep 30;351(14):1425-36 [15459304.001]
  • [Cites] Am J Med. 1992 Aug;93(2):171-6 [1497013.001]
  • [Cites] Arch Dis Child. 1977 May;52(5):360-7 [559475.001]
  • [Cites] Biochem Biophys Res Commun. 2001 Jan 26;280(3):640-5 [11162569.001]
  • [Cites] Nat Genet. 1997 Jul;16(3):235-42 [9207787.001]
  • [Cites] Pathol Res Pract. 2005;201(1):55-60 [15807312.001]
  • [Cites] J Comput Assist Tomogr. 1986 Nov-Dec;10 (6):1047-9 [3023458.001]
  • (PMID = 20108035.001).
  • [ISSN] 1573-2568
  • [Journal-full-title] Digestive diseases and sciences
  • [ISO-abbreviation] Dig. Dis. Sci.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


7. Abe K, Thung SN, Wu HC, Tran TT, Le Hoang P, Truong KD, Inui A, Jang JJ, Su IJ: Pre-S2 deletion mutants of hepatitis B virus could have an important role in hepatocarcinogenesis in Asian children. Cancer Sci; 2009 Dec;100(12):2249-54
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Although many studies on the risk factors and their carcinogenesis in adult hepatocellular carcinoma (HCC) have been reported, they remain poorly understood in childhood HCC.
  • The HBV pre-S2 deletion mutant at nt 4-57 which has a CD8 T-cell epitope could be responsible for the emergence and aggressive outcome of childhood HCC.
  • [MeSH-major] Carcinoma, Hepatocellular / etiology. Gene Deletion. Hepatitis B Surface Antigens / genetics. Hepatitis B virus / genetics. Liver Neoplasms / etiology. Protein Precursors / genetics

  • Genetic Alliance. consumer health - Hepatitis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19719772.001).
  • [ISSN] 1349-7006
  • [Journal-full-title] Cancer science
  • [ISO-abbreviation] Cancer Sci.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Hepatitis B Surface Antigens; 0 / Protein Precursors; 0 / presurface protein 2, hepatitis B surface antigen
  •  go-up   go-down


8. Chiba T, Yokosuka O, Fukai K, Hirasawa Y, Tada M, Mikata R, Imazeki F, Taniguchi H, Iwama A, Miyazaki M, Ochiai T, Saisho H: Identification and investigation of methylated genes in hepatoma. Eur J Cancer; 2005 May;41(8):1185-94
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Identification and investigation of methylated genes in hepatoma.
  • Previous microarray analysis demonstrated that 14 genes, including hepatocyte growth factor activator inhibitor 2/placental bikunin (HAI2/PB) gene, showed particularly high inductions after 5-aza-2'deoxycytidine (5Aza-dC) treatment in multiple hepatoma cell lines.
  • Aberrant methylation in primary hepatoma tissues was also examined using methylation-specific polymerase chain reaction (MSP).
  • Genes for E-cadherin, collagen type I alpha 2 (COL1A2), insulin-like growth factor binding protein 2 (IGFBP2), connective tissue growth factor (CTGF) and fibronectin 1 exhibited aberrant methylation in several hepatoma cell lines.
  • In further studies of 24 primary hepatoma tissues, methylation signals for COL1A2, IGFBP2, CTGF and fibronectin 1 were detected in 13, 18, 4 and 10 patients, respectively.
  • In conclusion, aberrant methylation of COL1A2, IGFBP2, CTGF and fibronectin 1 genes were detected in hepatoma cell lines.
  • The results of MSP in hepatoma tissues suggested that some of these genes might be involved in the development or progression of hepatoma.
  • [MeSH-major] Carcinoma, Hepatocellular / genetics. DNA Methylation. DNA, Complementary / genetics. Liver Neoplasms / genetics. Oncogenes / genetics
  • [MeSH-minor] Adult. Aged. Collagen Type I / genetics. Connective Tissue Growth Factor. CpG Islands / genetics. Female. Fibronectins / genetics. Histones / genetics. Humans. Immediate-Early Proteins / genetics. Insulin-Like Growth Factor Binding Protein 2 / genetics. Intercellular Signaling Peptides and Proteins / genetics. Male. Microarray Analysis / methods. Middle Aged. RNA, Messenger / metabolism. Reverse Transcriptase Polymerase Chain Reaction / methods

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15911243.001).
  • [ISSN] 0959-8049
  • [Journal-full-title] European journal of cancer (Oxford, England : 1990)
  • [ISO-abbreviation] Eur. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / CTGF protein, human; 0 / Collagen Type I; 0 / DNA, Complementary; 0 / Fibronectins; 0 / Histones; 0 / Immediate-Early Proteins; 0 / Insulin-Like Growth Factor Binding Protein 2; 0 / Intercellular Signaling Peptides and Proteins; 0 / RNA, Messenger; 0 / collagen type I, alpha 1 chain; 139568-91-5 / Connective Tissue Growth Factor
  •  go-up   go-down


9. Wilson FD, Fitzgerald SD, Kiupel M, Walker RL, Williams CB, Todd DJ: Occurrence of hepatocellular carcinoma in an adult male Nile lechwe (Kobus megaceros). J Zoo Wildl Med; 2007 Jun;38(2):329-32
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Occurrence of hepatocellular carcinoma in an adult male Nile lechwe (Kobus megaceros).
  • The liver was grossly enlarged and contained a smooth-surfaced nodular mass that occupied the majority of the right lobe of the liver.
  • The mass had a liver-like appearance exhibiting a tan-red coloration but having a soft consistency.
  • To our knowledge, this is the first report in the scientific literature of a naturally occurring case of hepatocellular carcinoma in a Nile lechwe or in any antelope species.
  • [MeSH-major] Antelopes. Carcinoma, Hepatocellular / veterinary. Liver Neoplasms / veterinary

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17679519.001).
  • [ISSN] 1042-7260
  • [Journal-full-title] Journal of zoo and wildlife medicine : official publication of the American Association of Zoo Veterinarians
  • [ISO-abbreviation] J. Zoo Wildl. Med.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


10. Zhang GQ, Wang HB, Gao P, Fang CH, Chen GH: [Relationship of extrahepatic metastasis of primary hepatocellular carcinoma between circulative tumor cells in the blood of hepatoma patients]. Zhonghua Wai Ke Za Zhi; 2009 Dec 15;47(24):1857-9
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Relationship of extrahepatic metastasis of primary hepatocellular carcinoma between circulative tumor cells in the blood of hepatoma patients].
  • OBJECTIVE: To study the relationship between extrahepatic metastasis of primary hepatocellular carcinoma and circulative tumor cells in the blood of hepatoma patients.
  • METHODS: The immunomagnetic bead technique was employed to enrich and separate the hepatoma cells in the peripheral blood of preoperative and postoperative hepatoma patients.
  • The relationship between postoperative extrahepatic metastasis and hepatoma cells in peripheral blood cancer cells were analyzed.
  • The circulative tumor cells in the peripheral blood of hepatoma patients were enriched and separated by immunomagnetic bead technique.
  • They were identified as hepatoma cells by AFP immunohistochemistry.
  • Among 30 cases of hepatoma patients, the positive rate of hepatoma cells in the peripheral blood of preoperation and postoperation were 53.3% and 83.3% respectively.
  • CONCLUSIONS: Extrahepatic metastasis of primary hepatocellular carcinoma is obviously correlated to the positive tumor cells and the concentration in the peripheral blood of preoperative patients.
  • [MeSH-major] Carcinoma, Hepatocellular / pathology. Liver Neoplasms / pathology
  • [MeSH-minor] Adult. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Metastasis. Neoplasm Staging

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20193401.001).
  • [ISSN] 0529-5815
  • [Journal-full-title] Zhonghua wai ke za zhi [Chinese journal of surgery]
  • [ISO-abbreviation] Zhonghua Wai Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  •  go-up   go-down


11. Wang NY, Zhao W, Zhang D, Zhang YC, Duan MH: [Clinical application of avidin-biotin ELISA to detect serum hepatoma-specific gamma-glutamyltransferase in patients with primary hepatic cancer]. Zhonghua Zhong Liu Za Zhi; 2009 Feb;31(2):114-7
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical application of avidin-biotin ELISA to detect serum hepatoma-specific gamma-glutamyltransferase in patients with primary hepatic cancer].
  • OBJECTIVE: To detect serum hepatoma-specific datura stramonium lectin-tightly binding gamma-glutamyl transferase (DSA-GGT) in patients with primary hepatic cancer (PHC) by avidin-biotin ELISA method which was established in our laboratory, and carry on a study of its clinical application.
  • METHODS: To detect serum DSA-GGT in 45 healthy control subjects, 58 PHC patients and 203 non-PHC patients (including 36 patients with other tumors and 167 patients with benign liver diseases) with the method was established; meanwhile, AFP was detected by ELISA method.
  • [MeSH-major] Carcinoma, Hepatocellular / diagnosis. Liver Neoplasms / diagnosis. gamma-Glutamyltransferase / blood
  • [MeSH-minor] Adult. Avidin. Biotin. Enzyme-Linked Immunosorbent Assay / methods. Female. Humans. Male. Middle Aged. Sensitivity and Specificity. Young Adult. alpha-Fetoproteins / analysis

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • Hazardous Substances Data Bank. BIOTIN .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19538886.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / alpha-Fetoproteins; 1405-69-2 / Avidin; 6SO6U10H04 / Biotin; EC 2.3.2.2 / gamma-Glutamyltransferase
  •  go-up   go-down


12. Kar S, Wang M, Carr BI: alpha-Thrombin inhibits DNA synthesis in rat hepatocytes but not in hepatoma cells by receptor activation and proteolysis. Mol Cell Biochem; 2007 Oct;304(1-2):189-97
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] alpha-Thrombin inhibits DNA synthesis in rat hepatocytes but not in hepatoma cells by receptor activation and proteolysis.
  • It has also been shown to have a mitogenic effect on primary endothelial cells, vascular smooth muscle cells, fibroblasts and some tumor cells, but is an inhibitor of rat hepatocyte DNA synthesis on fibronectin matrix in cell culture.
  • We now report that prothrombin is converted to alpha-thrombin by primary cultures of normal adult rat hepatocytes and alpha-thrombin is also a potent inhibitor of hepatocytes DNA synthesis.
  • In contrast, rat hepatoma cells cultured under similar conditions were resistant to alpha-thrombin mediated DNA synthesis inhibition.
  • However, no appreciable cell detachment was observed.
  • [MeSH-major] Carcinoma, Hepatocellular / pathology. DNA / metabolism. Hepatocytes / drug effects. Receptors, Thrombin / metabolism. Thrombin / pharmacology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Cell Biol. 1991 Jan;112(2):335-44 [1988465.001]
  • [Cites] Blood. 2000 May 15;95(10):3133-8 [10807779.001]
  • [Cites] J Clin Invest. 1978 Nov;62(5):923-30 [361756.001]
  • [Cites] Nature. 1987 Oct 29-Nov 4;329(6142):849-50 [3670389.001]
  • [Cites] J Biol Chem. 2005 Feb 25;280(8):6409-15 [15582995.001]
  • [Cites] J Thromb Haemost. 2003 Mar;1(3):511-5 [12871459.001]
  • [Cites] Nature. 1991 Oct 17;353(6345):674-7 [1717851.001]
  • [Cites] Blood. 1990 Jul 1;76(1):1-16 [2194585.001]
  • [Cites] Hepatology. 1998 Feb;27(2):462-71 [9462645.001]
  • [Cites] Nature. 1979 Apr 19;278(5706):711-4 [431729.001]
  • [Cites] Thromb Res. 1979;14(6):969-73 [473131.001]
  • [Cites] J Biol Chem. 1980 Apr 10;255(7):3134-40 [6444635.001]
  • [Cites] J Gastroenterol. 1997 Aug;32(4):507-12 [9250899.001]
  • [Cites] J Mol Biol. 2003 Feb 21;326(3):721-35 [12581635.001]
  • [Cites] J Clin Invest. 1986 Jan;77(1):165-9 [2418059.001]
  • [Cites] Nature. 1994 Apr 14;368(6472):648-51 [8145852.001]
  • [Cites] Cancer Cell. 2006 Nov;10(5):355-62 [17097558.001]
  • [Cites] Nature. 1967 Dec 2;216(5118):857-8 [6074962.001]
  • [Cites] Biochem J. 1996 Jan 15;313 ( Pt 2):353-68 [8573065.001]
  • [Cites] J Cell Biochem. 1984;26(3):181-95 [6098590.001]
  • [Cites] Adv Biochem Eng Biotechnol. 2005;93:101-34 [15791946.001]
  • [Cites] Int J Hematol. 2001 Feb;73(2):145-50 [11372724.001]
  • [Cites] Cell Biol Int. 2007 Sep;31(9):929-38 [17490900.001]
  • [Cites] Blood. 1990 Sep 15;76(6):1173-80 [2119237.001]
  • [Cites] J Clin Invest. 1978 Apr;61(4):1102-6 [207723.001]
  • [Cites] J Neurooncol. 1999 Apr;42(2):131-6 [10421070.001]
  • [Cites] Cell Regul. 1990 May;1(6):453-63 [1963793.001]
  • [Cites] N Engl J Med. 1984 May 31;310(22):1427-31 [6201741.001]
  • [Cites] J Cell Biol. 1980 Apr;85(1):70-82 [7364876.001]
  • [Cites] Arch Int Physiol Biochim Biophys. 1993 Nov-Dec;101(6):357-9 [7511428.001]
  • [Cites] J Biol Chem. 1994 Jun 24;269(25):17104-10 [7516333.001]
  • [Cites] FEBS Lett. 1992 Apr 20;301(2):155-8 [1314739.001]
  • [Cites] Biochem J. 1994 Oct 1;303 ( Pt 1):227-31 [7945245.001]
  • [Cites] J Clin Invest. 1993 Jan;91(1):94-8 [8380817.001]
  • [Cites] Ann N Y Acad Sci. 1986;485:228-39 [3032044.001]
  • [Cites] Biochemistry. 1991 Oct 29;30(43):10363-70 [1931959.001]
  • [Cites] Proc Natl Acad Sci U S A. 1975 Jan;72(1):131-5 [1054489.001]
  • [Cites] Thromb Res. 2000 May 15;98(4):323-32 [10822079.001]
  • [Cites] Cell. 1991 Mar 22;64(6):1057-68 [1672265.001]
  • [Cites] J Biol Chem. 1987 Oct 15;262(29):14134-40 [2820995.001]
  • [Cites] J Thromb Thrombolysis. 2007 Aug;24(1):29-38 [17396228.001]
  • (PMID = 17516031.001).
  • [ISSN] 0300-8177
  • [Journal-full-title] Molecular and cellular biochemistry
  • [ISO-abbreviation] Mol. Cell. Biochem.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA82723
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Fibronectins; 0 / Nucleic Acid Synthesis Inhibitors; 0 / Receptors, Thrombin; 9001-26-7 / Prothrombin; 9007-49-2 / DNA; EC 3.4.21.5 / Thrombin
  •  go-up   go-down


13. Kok SH, Chui CH, Lam WS, Chen J, Lau FY, Cheng GY, Wong RS, Lai PP, Leung TW, Tang JC, Chan AS: Apoptotic activity of a novel synthetic cantharidin analogue on hepatoma cell lines. Int J Mol Med; 2006 May;17(5):945-9
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Apoptotic activity of a novel synthetic cantharidin analogue on hepatoma cell lines.
  • The cytotoxic activity of this analogue was screened on both Hep3B hepatocellular carcinoma and SK-Hep-1 liver adenocarcinoma cell lines by [3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium] (MTS) assay.
  • Morphological changes of hepatoma cell lines were recorded under an inverted microscope.
  • The possible tolerance of these analogues was further investigated using non-malignant haematological bone marrow primary culture.
  • CAN 032 showed a significant cytotoxic response on both hepatoma cell lines in which the potencies were comparable to that of cantharidin.
  • Phase contrast microscopy demonstrated that cell shrinkage, rounding, loss of adherent property and loss of colony-formation ability were induced.
  • [MeSH-minor] Adult. Antineoplastic Agents / chemical synthesis. Antineoplastic Agents / chemistry. Antineoplastic Agents / pharmacology. Bone Marrow Cells / cytology. Bone Marrow Cells / drug effects. Carcinoma, Hepatocellular / genetics. Carcinoma, Hepatocellular / pathology. Carcinoma, Hepatocellular / physiopathology. Cell Cycle / drug effects. Cell Line, Tumor. Cell Size / drug effects. DNA Fragmentation / drug effects. Dose-Response Relationship, Drug. Female. Humans. Male. Microscopy, Phase-Contrast. Molecular Structure. Thiazoles / chemical synthesis. Thiazoles / pharmacology

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CANTHARIDINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16596285.001).
  • [ISSN] 1107-3756
  • [Journal-full-title] International journal of molecular medicine
  • [ISO-abbreviation] Int. J. Mol. Med.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / CAN 032; 0 / Thiazoles; IGL471WQ8P / Cantharidin
  •  go-up   go-down


14. Kinoshita Y, Tajiri T, Souzaki R, Tatsuta K, Higashi M, Izaki T, Takahashi Y, Taguchi T: Diagnostic value of lectin reactive alpha-fetoprotein for neoinfantile hepatic tumors and malignant germ cell tumors: preliminary study. J Pediatr Hematol Oncol; 2008 Jun;30(6):447-50
Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diagnostic value of lectin reactive alpha-fetoprotein for neoinfantile hepatic tumors and malignant germ cell tumors: preliminary study.
  • BACKGROUND AND PURPOSE: The serum alpha-fetoprotein (AFP) level has been used as a tumor marker for hepatoblastoma, and malignant germ cell tumors in pediatric patients.
  • The AFP has 3 isoforms (L1, L2, L3), and the usefulness of the L3 fraction as a diagnostic marker for the adult hepatocellular carcinoma is well known.
  • MATERIALS AND METHODS: From 2003 to 2006, two cases of hepatoblastoma, and 5 cases of germ cell tumor, all of which were neoinfantile, were treated in our department.
  • DISCUSSION: Our results indicated that the level of the L3 fraction accurately confirmed the existence, or the malignant potential of hepatic tumor or germ cell tumor.
  • [MeSH-major] Biomarkers, Tumor / blood. Hepatoblastoma / blood. Liver Neoplasms / blood. Neoplasms, Germ Cell and Embryonal / blood. alpha-Fetoproteins / analysis

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18525461.001).
  • [ISSN] 1077-4114
  • [Journal-full-title] Journal of pediatric hematology/oncology
  • [ISO-abbreviation] J. Pediatr. Hematol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Lectins; 0 / Protein Isoforms; 0 / alpha-Fetoproteins
  •  go-up   go-down


15. Asechi H, Hatano E, Nitta T, Tada M, Iwaisako K, Tamaki N, Nagata H, Narita M, Yanagida A, Ikai I, Uemoto S: Resistance to cisplatin-induced apoptosis via PI3K-dependent survivin expression in a rat hepatoma cell line. Int J Oncol; 2010 Jul;37(1):89-96
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Resistance to cisplatin-induced apoptosis via PI3K-dependent survivin expression in a rat hepatoma cell line.
  • Hepatocellular carcinoma (HCC) is known to be resistant to chemotherapy.
  • Survivin, a member of the inhibitor of apoptosis proteins, is overexpressed in most cancers but is absent in most normal adult tissue.
  • We confirmed induction of survivin expression in hepatoma in the N-diethylnitrosamine (DEN) induced rat and in the rat hepatoma cell line (K-251).
  • We examined cell proliferation after treatment with cisplatin (CDDP) in the presence and absence of siRNA or the phosphatidylinositol 3-kinase (PI3K) inhibitor LY294002 to suppress survivin or PI3K/Akt, respectively.
  • Expression of survivin was observed primary in the nuclei and in the cytoplasm with immunohistochemistry.
  • Expression of survivin was also observed primarily in the nuclei and in the cytoplasm of the K-251 rat hepatoma cell line.
  • Our results indicate that survivin expression via PI3K contributes to resistance to CDDP-induced apoptosis in a rat hepatoma cell line.
  • [MeSH-major] Apoptosis / drug effects. Carcinoma, Hepatocellular / genetics. Cisplatin / pharmacology. Drug Resistance, Neoplasm / genetics. Liver Neoplasms, Experimental / genetics. Microtubule-Associated Proteins / genetics. Phosphatidylinositol 3-Kinases / physiology
  • [MeSH-minor] Animals. Antineoplastic Agents / pharmacology. Cell Line, Tumor. Cells, Cultured. Diethylnitrosamine. Gene Expression Regulation, Neoplastic / drug effects. Male. RNA, Small Interfering / pharmacology. Rats. Rats, Sprague-Dawley

  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. N-NITROSODIETHYLAMINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20514400.001).
  • [ISSN] 1791-2423
  • [Journal-full-title] International journal of oncology
  • [ISO-abbreviation] Int. J. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Birc5 protein, rat; 0 / Microtubule-Associated Proteins; 0 / RNA, Small Interfering; 3IQ78TTX1A / Diethylnitrosamine; EC 2.7.1.- / Phosphatidylinositol 3-Kinases; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


16. Guillouzo A, Corlu A, Aninat C, Glaise D, Morel F, Guguen-Guillouzo C: The human hepatoma HepaRG cells: a highly differentiated model for studies of liver metabolism and toxicity of xenobiotics. Chem Biol Interact; 2007 May 20;168(1):66-73
Hazardous Substances Data Bank. AFLATOXIN B1 .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The human hepatoma HepaRG cells: a highly differentiated model for studies of liver metabolism and toxicity of xenobiotics.
  • Although they have several important limitations primary human hepatocytes still represent the in vitro gold standard model for xenobiotic metabolism and toxicity studies.
  • The large use of human liver cell lines either from tumoral origin or obtained by oncogenic immortalisation is prevented by the loss of various liver-specific functions, especially many cytochrome P450 (CYP)-related enzyme activities.
  • We review here recent results obtained with a new human hepatoma cell line, named HepaRG, derived from a human hepatocellular carcinoma.
  • Moreover contrary to other human hepatoma cell lines including HepG2 cells, HepaRG cells express various CYPs (CYP1A2, 2B6, 2C9, 2E1, 3A4) and the nuclear receptors constitutive androstane receptor (CAR) and pregnane X receptor (PXR) at levels comparable to those found in cultured primary human hepatocytes.
  • They also express various other functions such phase 2 enzymes, apical and canalicular ABC transporters and basolateral solute carrier transporters, albumin, haptoglobin as well as aldolase B that is a specific marker of adult hepatocytes.
  • HepaRG cells could represent a surrogate to primary human hepatocytes for xenobiotic metabolism and toxicity studies and even more, a unique model system for analysing genotoxic compounds.
  • [MeSH-major] Carcinoma, Hepatocellular / metabolism. Liver Neoplasms / metabolism. Models, Biological. Xenobiotics / toxicity
  • [MeSH-minor] Aflatoxin B1 / poisoning. Biomarkers / metabolism. Cell Differentiation. Cell Line, Tumor. Cytochrome P-450 Enzyme System / genetics. Cytochrome P-450 Enzyme System / metabolism. Female. Hepatocytes / cytology. Hepatocytes / drug effects. Hepatocytes / metabolism. Humans. Inhibitory Concentration 50. Metabolic Detoxication, Phase I. Metabolic Detoxication, Phase II. RNA, Messenger / analysis. Receptors, Cytoplasmic and Nuclear / genetics. Receptors, Cytoplasmic and Nuclear / metabolism. Receptors, Steroid / genetics. Receptors, Steroid / metabolism. Transcription Factors / genetics. Transcription Factors / metabolism

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • Cellosaurus - a cell line knowledge resource. culture/stock collections - Cellosaurus - a cell line knowledge resource .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17241619.001).
  • [ISSN] 0009-2797
  • [Journal-full-title] Chemico-biological interactions
  • [ISO-abbreviation] Chem. Biol. Interact.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Biomarkers; 0 / RNA, Messenger; 0 / Receptors, Cytoplasmic and Nuclear; 0 / Receptors, Steroid; 0 / Transcription Factors; 0 / Xenobiotics; 0 / constitutive androstane receptor; 0 / pregnane X receptor; 9035-51-2 / Cytochrome P-450 Enzyme System; 9N2N2Y55MH / Aflatoxin B1
  • [Number-of-references] 23
  •  go-up   go-down


17. Yan K, Chen MH, Dai Y, Shen L, Jiang XL: [Results of enhanced ultrasonography in assessing hepatoma treated with radiofrequency ablation]. Zhonghua Zhong Liu Za Zhi; 2005 Jan;27(1):41-4
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Results of enhanced ultrasonography in assessing hepatoma treated with radiofrequency ablation].
  • METHODS: Eighteen patients with 17 primary hepatocellular carcinoma and 1 hepatic metastasis were studied.
  • [MeSH-major] Carcinoma, Hepatocellular / ultrasonography. Catheter Ablation. Liver Neoplasms / ultrasonography
  • [MeSH-minor] Adult. Aged. Female. Humans. Male. Middle Aged

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15771798.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  •  go-up   go-down


18. Masuda T, Beppu T, Horino K, Komori H, Hayashi H, Okabe H, Ootao R, Horlad H, Baba Y, Miyase S, Takamori H, Baba H: Occurrence of hepatocellular carcinoma after hepatoblastoma resection in an adult with hepatitis C virus. Hepatol Res; 2009 May;39(5):525-30

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Occurrence of hepatocellular carcinoma after hepatoblastoma resection in an adult with hepatitis C virus.
  • In patients with no indication for a hepatic resection, the prognosis of adult hepatoblastoma is quite poor.
  • A 54-year-old man with hepatitis C virus-associated liver cirrhosis was initially treated with a hepatic resection for a hepatic tumor, 3 cm in diameter.
  • The tumor consisted of osteoid-like and cartilaginous foci, myxomatous stroma, and poorly differentiated hepatocellular carcinomatous cells and was diagnosed as a mixed epithelial and mesenchymal hepatoblastoma.
  • Two years after the first operation, multicentric hepatocellular carcinomas developed in the remnant liver and were successfully treated with a secondary hepatic resection combined with radio-frequency ablation.
  • To the best of our knowledge, the primary hepatoblastoma was the smallest such tumor reported and this is the first report of a metachronous hepatoblastoma and hepatocellular carcinoma in an adult hepatitis patient.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19207587.001).
  • [ISSN] 1386-6346
  • [Journal-full-title] Hepatology research : the official journal of the Japan Society of Hepatology
  • [ISO-abbreviation] Hepatol. Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


19. Zhang W, Feng S, Yan S, Zhao Y, Li M, Sun J, Zhang FC, Cui Q, Dong Y: Incidence of malignancy in primary Sjogren's syndrome in a Chinese cohort. Rheumatology (Oxford); 2010 Mar;49(3):571-7
MedlinePlus Health Information. consumer health - Sjogren's Syndrome.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Incidence of malignancy in primary Sjogren's syndrome in a Chinese cohort.
  • OBJECTIVES: To evaluate the incidence of malignancies in a cohort of Chinese patients with primary Sjögren's syndrome (pSS) and to identify the risk factors of malignancy in pSS patients.
  • Different types of malignancy were observed including eight lymphomas, two myeloid myelomas and 19 solid tumours, which consisted of invasive thymoma, breast cancer, lung cancer, gastrointestinal adenocarcinoma, hepatoma, squamous cell carcinoma of tongue, uterine cervix cancer, renal carcinoma, thyroid carcinoma and mucoepidermoid carcinoma of parotid gland.
  • CONCLUSIONS: The current study confirms the increased incidence of lymphoma in Chinese patients with pSS, with the majority of B-cell non-Hodgkin's lymphoma.
  • [MeSH-minor] Adult. China / epidemiology. Epidemiologic Methods. Female. Humans. Lymphoma / epidemiology. Lymphoma / etiology. Male. Middle Aged

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20040528.001).
  • [ISSN] 1462-0332
  • [Journal-full-title] Rheumatology (Oxford, England)
  • [ISO-abbreviation] Rheumatology (Oxford)
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


20. Woodard LE, Keravala A, Jung WE, Wapinski OL, Yang Q, Felsher DW, Calos MP: Impact of hydrodynamic injection and phiC31 integrase on tumor latency in a mouse model of MYC-induced hepatocellular carcinoma. PLoS One; 2010 Jun 29;5(6):e11367
eagle-i research resources. PMID 20614008 (Special Collections) .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Impact of hydrodynamic injection and phiC31 integrase on tumor latency in a mouse model of MYC-induced hepatocellular carcinoma.
  • BACKGROUND: Hydrodynamic injection is an effective method for DNA delivery in mouse liver and is being translated to larger animals for possible clinical use.
  • METHODOLOGY/PRINCIPAL FINDINGS: To study whether hydrodynamic delivery alone, or in conjunction with delivery of phiC31 integrase for long-term transgene expression, could facilitate tumor formation, we used a transgenic mouse model in which sustained induction of the human C-MYC oncogene in the liver was followed by hydrodynamic injection.
  • In contrast, when active or inactive phiC31 integrase and donor plasmid were supplied to the mouse liver, the median tumor latency was 153 days, similar to mice receiving no injection.
  • However, in groups lacking phiC31 integrase, hydrodynamic injection appeared to contribute to C-MYC-induced hepatocellular carcinoma in adult mice.

  • COS Scholar Universe. author profiles.
  • Addgene Non-profit plasmid repository. clones/clone libraries - Get Article's Plasmids - Addgene (subscription/membership/fee required).
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Mol Ther. 2005 Oct;12(4):763-71 [16084128.001]
  • [Cites] Methods Mol Biol. 2005;308:99-106 [16082029.001]
  • [Cites] J Mol Biol. 2006 Mar 17;357(1):28-48 [16414067.001]
  • [Cites] Nat Biotechnol. 2006 Jun;24(6):687-96 [16732270.001]
  • [Cites] Gene Ther. 2006 Aug;13(15):1188-90 [16672982.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Aug 1;103(31):11730-5 [16864781.001]
  • [Cites] Hum Gene Ther. 2006 Aug;17(8):871-6 [16942446.001]
  • [Cites] Nucleic Acids Res. 2006;34(21):6298-304 [17098929.001]
  • [Cites] Curr Gene Ther. 2006 Dec;6(6):633-45 [17168696.001]
  • [Cites] Hum Gene Ther. 2006 Nov;17(11):1077-94 [17069535.001]
  • [Cites] Science. 2007 Jul 27;317(5837):477 [17656716.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Sep 11;104(37):14771-6 [17785413.001]
  • [Cites] Blood. 2008 Feb 15;111(4):1866-75 [17991809.001]
  • [Cites] Gene Ther. 2008 Mar;15(6):452-62 [18004400.001]
  • [Cites] Cancer Gene Ther. 2008 Apr;15(4):225-30 [18259214.001]
  • [Cites] Mol Ther. 2008 Jun;16(6):1098-104 [18398428.001]
  • [Cites] PLoS One. 2008;3(6):e2493 [18560566.001]
  • [Cites] Lymphat Res Biol. 2008;6(3-4):149-54 [19093787.001]
  • [Cites] Mol Ther. 2009 Jan;17(1):112-20 [19002165.001]
  • [Cites] Mol Ther. 2009 Mar;17(3):491-9 [19156134.001]
  • [Cites] BMC Biotechnol. 2009;9:31 [19341467.001]
  • [Cites] Mol Ther. 2010 Jan;18(1):161-70 [19844192.001]
  • [Cites] Gene Ther. 2010 Feb;17(2):217-26 [19847205.001]
  • [Cites] Mol Ther. 2010 Jul;18(7):1346-56 [20424600.001]
  • [Cites] Mol Biol Rep. 2010 Jul;37(6):2809-16 [19757154.001]
  • [Cites] Hum Gene Ther. 2010 Oct;21(10):1287-97 [20497035.001]
  • [Cites] Mol Cell Biol. 2001 Jun;21(12):3926-34 [11359900.001]
  • [Cites] Nat Biotechnol. 2002 Nov;20(11):1124-8 [12379870.001]
  • [Cites] Curr Biol. 2004 Jun 8;14(11):R425-7 [15182690.001]
  • [Cites] Nature. 2004 Oct 28;431(7012):1112-7 [15475948.001]
  • [Cites] Mod Pathol. 1996 Feb;9(2):95-8 [8657726.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Oct 1;93(20):10933-8 [8855286.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Mar 30;96(7):3940-4 [10097142.001]
  • [Cites] Hum Gene Ther. 1999 Jul 1;10(10):1735-7 [10428218.001]
  • [Cites] Gene Ther. 1999 Jul;6(7):1258-66 [10455434.001]
  • [Cites] Oncology. 1999;57(2):157-63 [10461064.001]
  • [Cites] Mol Cell. 1999 Aug;4(2):199-207 [10488335.001]
  • [Cites] PLoS Biol. 2004 Nov;2(11):e332 [15455033.001]
  • [Cites] Mol Ther. 2005 Mar;11(3):399-408 [15727936.001]
  • [Cites] Mol Ther. 2005 May;11(5):695-706 [15851008.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Jan 10;103(2):419-24 [16387861.001]
  • (PMID = 20614008.001).
  • [ISSN] 1932-6203
  • [Journal-full-title] PloS one
  • [ISO-abbreviation] PLoS ONE
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / T32 CA009302; United States / NCI NIH HHS / CA / CA89305-01A1; United States / NCI NIH HHS / CA / P01 CA034233; United States / NCI NIH HHS / CA / CA034233; United States / NHLBI NIH HHS / HL / R01 HL068112; United States / NCI NIH HHS / CA / R01 CA089305; United States / NHLBI NIH HHS / HL / HL068112; United States / NHLBI NIH HHS / HL / R56 HL068112; United States / NCI NIH HHS / CA / CA09302
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA Primers; EC 2.7.7.- / Integrases
  • [Other-IDs] NLM/ PMC2894073
  •  go-up   go-down


21. van der Sande MA, Waight PA, Mendy M, Zaman S, Kaye S, Sam O, Kahn A, Jeffries D, Akum AA, Hall AJ, Bah E, McConkey SJ, Hainaut P, Whittle HC: Long-term protection against HBV chronic carriage of Gambian adolescents vaccinated in infancy and immune response in HBV booster trial in adolescence. PLoS One; 2007 Aug 15;2(8):e753
MedlinePlus Health Information. consumer health - Hepatitis B.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Chronic infection with hepatitis B virus (HBV) arising in childhood is associated with hepatocellular carcinoma in adult life.
  • Between 1986 and 1990, approximately 120,000 Gambian newborns were enrolled in a randomised controlled trial to assess the effectiveness of infant HBV vaccination on the prevention of hepatocellular carcinoma in adulthood.
  • [MeSH-minor] Adolescent. Adult. Carcinoma, Hepatocellular / etiology. Carcinoma, Hepatocellular / virology. Child. Female. Gambia. Humans. Infant. Liver Neoplasms / etiology. Liver Neoplasms / virology. Male. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Lancet. 2000 Feb 12;355(9203):561-5 [10683019.001]
  • [Cites] J Infect Dis. 2006 Jun 1;193(11):1528-35 [16652281.001]
  • [Cites] Pediatrics. 2001 Apr;107(4):626-31 [11335734.001]
  • [Cites] BMJ. 2002 Sep 14;325(7364):569 [12228132.001]
  • [Cites] Scand J Infect Dis. 2002;34(8):610-4 [12238579.001]
  • [Cites] Vaccine. 2002 Oct 4;20(29-30):3472-6 [12297392.001]
  • [Cites] Pediatr Infect Dis J. 2003 Feb;22(2):157-63 [12586980.001]
  • [Cites] Cancer Res. 1987 Nov 1;47(21):5782-7 [2822233.001]
  • [Cites] J Med Virol. 1988 Apr;24(4):377-84 [3367136.001]
  • [Cites] Lancet. 1991 Mar 30;337(8744):747-50 [1672389.001]
  • [Cites] J Hepatol. 1994 Aug;21(2):250-4 [7989718.001]
  • [Cites] J Infect Dis. 1997 Jun;175(6):1494-7 [9180192.001]
  • [Cites] Clin Infect Dis. 1998 Apr;26(4):933-7 [9564478.001]
  • [Cites] Vaccine. 1998 Apr;16(6):624-9 [9569474.001]
  • [Cites] J Infect Dis. 1999 Feb;179(2):489-92 [9878036.001]
  • [Cites] Vaccine. 1999 Apr 23;17(17):2162-5 [10367949.001]
  • [Cites] Vaccine. 1999 Jun 4;17(20-21):2661-6 [10418916.001]
  • [Cites] Vaccine. 1999 Aug 6;17(23-24):2946-50 [10462228.001]
  • [Cites] Vaccine. 2005 Dec 30;23(50):5792-7 [16303217.001]
  • [Cites] J Clin Virol. 2005 Dec;34 Suppl 1:S1-3 [16461208.001]
  • [Cites] Vaccine. 2000 Nov 22;19(7-8):877-85 [11115711.001]
  • (PMID = 17710152.001).
  • [ISSN] 1932-6203
  • [Journal-full-title] PloS one
  • [ISO-abbreviation] PLoS ONE
  • [Language] eng
  • [Grant] United Kingdom / Medical Research Council / / MC/ U190071425; United Kingdom / Medical Research Council / /
  • [Publication-type] Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Hepatitis B Vaccines
  • [Other-IDs] NLM/ PMC1940311
  • [General-notes] NLM/ Original DateCompleted: 20070822
  •  go-up   go-down


22. Fang CH, Lu CM, Huang YP, Li XF, Fan YF, Yang J, Xiang N, Pan JH: [Study on the application of value of digital medical technology in the operation on primary liver cancer]. Zhonghua Wai Ke Za Zhi; 2009 Apr 1;47(7):523-6
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Study on the application of value of digital medical technology in the operation on primary liver cancer].
  • OBJECTIVE: To study the clinical application of digital medical in the operation on primary liver cancer.
  • METHODS: The patients (n=11) with primary hepatic carcinoma treated between February and July 2008, including 9 cases of hepatocellular carcinoma, 2 cases of cholangiocellular carcinoma, were scanned using 64 slices helicon computerized tomography (CT) and the datasets was collected.
  • Then the hepatectomy in treatment of hepatoma and implanting of catheter were simulated with the force-feedback equipment (PHANToM).
  • RESULTS: The reconstructed models were true to life, and their spatial disposition and correlation were shown clearly; Blood supply of primary liver cancer could be seen easily.
  • CONCLUSIONS: Digital medical benefited knowing the relationship between primary liver cancer and the intrahepatic pipe.
  • It gave an advantage to complete primary liver cancer resection with more liver volume remained.
  • [MeSH-major] Computer Simulation. Liver Neoplasms / surgery. User-Computer Interface
  • [MeSH-minor] Adult. Aged. Female. Follow-Up Studies. Hepatectomy / methods. Humans. Image Processing, Computer-Assisted. Imaging, Three-Dimensional. Liver / radiography. Liver / surgery. Male. Middle Aged. Models, Anatomic. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Liver cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19595211.001).
  • [ISSN] 0529-5815
  • [Journal-full-title] Zhonghua wai ke za zhi [Chinese journal of surgery]
  • [ISO-abbreviation] Zhonghua Wai Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  •  go-up   go-down


23. Liu J, Xie Y, Merrick BA, Shen J, Ducharme DM, Collins J, Diwan BA, Logsdon D, Waalkes MP: Transplacental arsenic plus postnatal 12-O-teradecanoyl phorbol-13-acetate exposures associated with hepatocarcinogenesis induce similar aberrant gene expression patterns in male and female mouse liver. Toxicol Appl Pharmacol; 2006 Jun 15;213(3):216-23
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Transplacental arsenic plus postnatal 12-O-teradecanoyl phorbol-13-acetate exposures associated with hepatocarcinogenesis induce similar aberrant gene expression patterns in male and female mouse liver.
  • Our prior work shows that in utero arsenic exposure alone is a complete transplacental carcinogen, producing hepatocellular carcinoma in adult male offspring but not in females.
  • The dermal application of TPA (2 mug/0.1 ml acetone, twice/week for 21 weeks) after transplacental arsenic did not further increase arsenic-induced liver tumor formation in adult males but significantly increased liver tumor formation in adult females.
  • Thus, for comparison, liver tumors and normal liver samples taken from adult male and female mice at necropsy were analyzed for aberrant gene/protein expression by microarray, real-time RT-PCR and Western blot analysis.
  • Arsenic/TPA treatment resulted in increased expression of alpha-fetoprotein, k-ras, c-myc, estrogen receptor-alpha, cyclin D1, cdk2na, plasminogen activator inhibitor-1, cytokeratin-8, cytokeratin-18, glutathione S-transferases and insulin-like growth factor binding proteins in liver and liver tumors from both male and female mice.
  • Alterations in these gene products were associated with arsenic/TPA-induced liver tumors, regardless of sex.
  • Thus, transplacental arsenic plus postnatal TPA exposure induced similar aberrant gene expression patterns in male and female mouse liver, which are persistent and potentially important to the mechanism of arsenic initiation of hepatocarcinogenesis.
  • [MeSH-major] Arsenic / toxicity. Gene Expression Regulation / drug effects. Liver / drug effects. Liver Neoplasms / metabolism. Prenatal Exposure Delayed Effects. Tetradecanoylphorbol Acetate / toxicity


24. Dvorák Z, Vrzal R, Starha P, Klanicová A, Trávnícek Z: Effects of dinuclear copper(II) complexes with 6-(benzylamino)purine derivatives on AhR and PXR dependent expression of cytochromes P450 CYP1A2 and CYP3A4 genes in primary cultures of human hepatocytes. Toxicol In Vitro; 2010 Mar;24(2):425-9
Hazardous Substances Data Bank. COPPER, ELEMENTAL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effects of dinuclear copper(II) complexes with 6-(benzylamino)purine derivatives on AhR and PXR dependent expression of cytochromes P450 CYP1A2 and CYP3A4 genes in primary cultures of human hepatocytes.
  • As models, primary cultures of human hepatocytes and human hepatoma cells HepG2 transiently transfected with a plasmid containing dioxin-responsive element fused to the luciferase reporter gene (DRE-LUC) have been chosen.
  • It has been found that the tested complexes 1-6 did not significantly induce the expression of CYP1A2 and CYP3A4 mRNAs in the concentration range of 0.1-10.0microM, in three different primary human hepatocyte cultures after 24h of the treatment.
  • [MeSH-minor] Adult. Aged. Cells, Cultured. Gene Expression Regulation, Enzymologic / drug effects. Hepatocytes / drug effects. Hepatocytes / metabolism. Humans. Male. Middle Aged. Molecular Structure. RNA, Messenger / genetics. RNA, Messenger / metabolism

  • Hazardous Substances Data Bank. BENZYLADENINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2009 Elsevier Ltd. All rights reserved.
  • (PMID = 19854261.001).
  • [ISSN] 1879-3177
  • [Journal-full-title] Toxicology in vitro : an international journal published in association with BIBRA
  • [ISO-abbreviation] Toxicol In Vitro
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Benzyl Compounds; 0 / Purines; 0 / RNA, Messenger; 0 / Receptors, Aryl Hydrocarbon; 0 / Receptors, Steroid; 0 / pregnane X receptor; 789U1901C5 / Copper; EC 1.14.13.67 / CYP3A4 protein, human; EC 1.14.14.1 / CYP1A2 protein, human; EC 1.14.14.1 / Cytochrome P-450 CYP1A2; EC 1.14.14.1 / Cytochrome P-450 CYP3A; KXG6A989PS / benzylaminopurine
  •  go-up   go-down


25. Okudaira T, Tomita M, Uchihara JN, Matsuda T, Ishikawa C, Kawakami H, Masuda M, Tanaka Y, Ohshiro K, Takasu N, Mori N: NIK-333 inhibits growth of human T-cell leukemia virus type I-infected T-cell lines and adult T-cell leukemia cells in association with blockade of nuclear factor-kappaB signal pathway. Mol Cancer Ther; 2006 Mar;5(3):704-12
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] NIK-333 inhibits growth of human T-cell leukemia virus type I-infected T-cell lines and adult T-cell leukemia cells in association with blockade of nuclear factor-kappaB signal pathway.
  • Adult T-cell leukemia (ATL) is caused by human T-cell leukemia virus type I (HTLV-I) and remains incurable.
  • NIK-333, a novel synthetic retinoid, prevents the recurrence of human hepatoma after surgical resection of primary tumors.
  • We explored the effects of NIK-333 on HTLV-I-infected T-cell lines and ATL cells.
  • NIK-333 inhibited cell proliferation, induced G1 arrest, and resulted in massive apoptosis in all tested HTLV-I-infected T-cell lines and ATL cells, whereas little effect was observed on normal peripheral blood mononuclear cells.
  • Further analysis showed that NIK-333 inactivated nuclear factor-kappaB in HTLV-I-infected T-cell lines.
  • In animal studies, treatment with NIK-333 (100 mg/kg given orally every other day) produced partial inhibition of growth of tumors of a HTLV-I-infected T-cell line transplanted s.c. in severe combined immunodeficient mice.
  • [MeSH-major] HTLV-I Infections / drug therapy. Human T-lymphotropic virus 1. Leukemia, T-Cell / drug therapy. Leukemia-Lymphoma, Adult T-Cell / drug therapy. NF-kappa B / antagonists & inhibitors. Retinoids / therapeutic use
  • [MeSH-minor] Animals. Apoptosis. Cell Line, Transformed. Cell Line, Tumor. Cyclin D1 / metabolism. Cyclin D2. Cyclins / metabolism. Down-Regulation. Female. Humans. Inhibitor of Apoptosis Proteins / metabolism. Mice. Mice, Inbred Strains. Signal Transduction. T-Lymphocytes / virology. X-Linked Inhibitor of Apoptosis Protein / metabolism

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16546985.001).
  • [ISSN] 1535-7163
  • [Journal-full-title] Molecular cancer therapeutics
  • [ISO-abbreviation] Mol. Cancer Ther.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CCND2 protein, human; 0 / Cyclin D2; 0 / Cyclins; 0 / Inhibitor of Apoptosis Proteins; 0 / NF-kappa B; 0 / Retinoids; 0 / X-Linked Inhibitor of Apoptosis Protein; 11ALM7A4RV / (2E,4E,6E,10E)-3,7,11,15-tetramethyl-2,4,6,10,14-hexadecapentaenoic acid; 136601-57-5 / Cyclin D1
  •  go-up   go-down


26. Bozzo C, Tiberio R, Graziola F, Pertusi G, Valente G, Colombo E, Small PL, Leigheb G: A Mycobacterium ulcerans toxin, mycolactone, induces apoptosis in primary human keratinocytes and in HaCaT cells. Microbes Infect; 2010 Dec;12(14-15):1258-63
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A Mycobacterium ulcerans toxin, mycolactone, induces apoptosis in primary human keratinocytes and in HaCaT cells.
  • In contrast, mycolactone A/B was devoid of toxicity neither on human hepatoma HuH7 nor on human embryonic kidney HEK 293 T cell lines.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Institut Pasteur. Published by Elsevier SAS. All rights reserved.
  • (PMID = 20800104.001).
  • [ISSN] 1769-714X
  • [Journal-full-title] Microbes and infection
  • [ISO-abbreviation] Microbes Infect.
  • [Language] ENG
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Lactones; 0 / Macrolides; 0 / mycolactone A; 0 / mycolactone B
  •  go-up   go-down


27. Kim S, Dere E, Burgoon LD, Chang CC, Zacharewski TR: Comparative analysis of AhR-mediated TCDD-elicited gene expression in human liver adult stem cells. Toxicol Sci; 2009 Nov;112(1):229-44
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparative analysis of AhR-mediated TCDD-elicited gene expression in human liver adult stem cells.
  • Time course and dose-response studies were conducted in HL1-1 cells, a human liver cell line with stem cell-like characteristics, to assess the differential gene expression elicited by 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) compared with other established models.
  • Comparative analysis of HL1-1 differential gene expression to human HepG2 data identified 74 genes with comparable temporal expression profiles including 12 putative primary responses.
  • Furthermore, comparative analysis of HL1-1 cells with mouse Hepa1c1c7 hepatoma cell lines and C57BL/6 hepatic tissue identified 18 and 32 commonly regulated orthologous genes, respectively, with functions associated with signal transduction, transcriptional regulation, metabolism and transport.
  • [MeSH-major] Gene Expression Profiling. Liver / drug effects. Receptors, Aryl Hydrocarbon / physiology. Stem Cells / drug effects. Tetrachlorodibenzodioxin / toxicity

  • MedlinePlus Health Information. consumer health - Stem Cells.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Methods Mol Biol. 2000;132:365-86 [10547847.001]
  • [Cites] Biochem Pharmacol. 2000 Oct 15;60(8):1129-42 [11007951.001]
  • [Cites] Regul Toxicol Pharmacol. 2000 Aug;32(1):56-67 [11029269.001]
  • [Cites] Toxicol Sci. 2001 Jan;59(1):17-36 [11134541.001]
  • [Cites] Toxicol Sci. 2001 Sep;63(1):65-73 [11509745.001]
  • [Cites] Toxicol In Vitro. 2001 Dec;15(6):741-53 [11698176.001]
  • [Cites] Toxicol Lett. 2002 Feb 28;127(1-3):153-60 [12052653.001]
  • [Cites] Nat Rev Genet. 2002 Aug;3(8):579-88 [12154381.001]
  • [Cites] Biotechniques. 2003 Feb;34(2):374-8 [12613259.001]
  • [Cites] Genome Biol. 2003;4(5):P3 [12734009.001]
  • [Cites] Toxicol Sci. 2003 Jun;73(2):386-402 [12657743.001]
  • [Cites] Toxicol Sci. 2003 Jun;73(2):207-8 [12700407.001]
  • [Cites] Nat Rev Drug Discov. 2003 Jul;2(7):542-53 [12815380.001]
  • [Cites] Nature. 2003 Aug 21;424(6951):870-2 [12931155.001]
  • [Cites] Toxicol Lett. 2004 Apr 1;149(1-3):361-9 [15093282.001]
  • [Cites] Mutat Res. 2004 May 18;549(1-2):79-99 [15120964.001]
  • [Cites] Toxicol Sci. 2004 Jun;79(2):214-23 [15014205.001]
  • [Cites] Nucleic Acids Res. 2004;32(15):4512-23 [15328365.001]
  • [Cites] Biochem Biophys Res Commun. 2004 Aug 27;321(3):707-15 [15358164.001]
  • [Cites] J Biopharm Stat. 2004 Aug;14(3):647-70 [15468757.001]
  • [Cites] Carcinogenesis. 1997 Jun;18(6):1177-82 [9214600.001]
  • [Cites] Environ Health Perspect. 1998 Apr;106 Suppl 2:755-60 [9599727.001]
  • [Cites] Bull Environ Contam Toxicol. 1998 Nov;61(5):557-68 [9841714.001]
  • [Cites] Carcinogenesis. 2005 Feb;26(2):495-502 [15513931.001]
  • [Cites] Bioinformatics. 2005 Apr 1;21(7):1078-83 [15513988.001]
  • [Cites] Toxicol Sci. 2005 Jun;85(2):1048-63 [15800033.001]
  • [Cites] Toxicol Sci. 2005 Oct;87(2):508-19 [16049271.001]
  • [Cites] Toxicol Sci. 2006 Apr;90(2):558-68 [16403854.001]
  • [Cites] BMC Genomics. 2006;7:80 [16611356.001]
  • [Cites] BMC Genomics. 2006;7:217 [16934159.001]
  • [Cites] Mol Nutr Food Res. 2006 Oct;50(10):897-907 [16977593.001]
  • [Cites] Toxicol Sci. 2006 Dec;94(2):398-416 [16960034.001]
  • [Cites] Toxicology. 2007 Feb 28;231(1):1-10 [17208344.001]
  • [Cites] Pharmacogenomics. 2007 Mar;8(3):287-91 [17324117.001]
  • [Cites] Toxicol Sci. 2007 Jul;98(1):5-38 [17569696.001]
  • [Cites] Biochem Pharmacol. 2007 Aug 1;74(3):496-503 [17568565.001]
  • [Cites] Toxicol Sci. 2008 Mar;102(1):61-75 [18042819.001]
  • [Cites] Mol Pharmacol. 2008 Mar;73(3):769-77 [18089838.001]
  • [Cites] Toxicol Sci. 2008 Jun;103(2):285-97 [18343893.001]
  • (PMID = 19684285.001).
  • [ISSN] 1096-0929
  • [Journal-full-title] Toxicological sciences : an official journal of the Society of Toxicology
  • [ISO-abbreviation] Toxicol. Sci.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Receptors, Aryl Hydrocarbon; DO80M48B6O / Tetrachlorodibenzodioxin
  • [Other-IDs] NLM/ PMC2769060
  •  go-up   go-down


28. Liu YB, Jian ZX, Ou JR, Liu ZX: [Treatment and surgery of primary hepatic cancer with portal vengus tumor thrombosis]. Zhonghua Wai Ke Za Zhi; 2005 Apr 1;43(7):436-8
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Treatment and surgery of primary hepatic cancer with portal vengus tumor thrombosis].
  • OBJECTIVE: To study the methods of surgery for hepatocellular carcinoma (HCC) with tumor thrombi in portal vein (TTPV).
  • 101 patients had operation treatment, 23 of them underwent hepatoma resection, and average survival time was 10.9 months; 78 patients underwent hepatoma resection and removal of tumor thrombi, and average survival time was 26.8 months.
  • CONCLUSIONS: Operation treatment can comparatively extend the survival time of hepatocellular carcinoma with tumor thrombi in portal vein patients, and the best choice is hepatoma resection and removal of tumor thrombi, hepatic artery and portal vein chemoembolization after operation can enhance the effect.
  • [MeSH-major] Carcinoma, Hepatocellular / surgery. Hepatectomy / methods. Liver Neoplasms / surgery. Neoplastic Cells, Circulating. Portal Vein / pathology
  • [MeSH-minor] Adult. Aged. Chemoembolization, Therapeutic. Combined Modality Therapy. Female. Humans. Male. Middle Aged. Neoadjuvant Therapy. Retrospective Studies. Survival Rate

  • Genetic Alliance. consumer health - Portal thrombosis.
  • Genetic Alliance. consumer health - Thrombosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15854368.001).
  • [ISSN] 0529-5815
  • [Journal-full-title] Zhonghua wai ke za zhi [Chinese journal of surgery]
  • [ISO-abbreviation] Zhonghua Wai Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  •  go-up   go-down


29. Cavard C, Terris B, Grimber G, Christa L, Audard V, Radenen-Bussiere B, Simon MT, Renard CA, Buendia MA, Perret C: Overexpression of regenerating islet-derived 1 alpha and 3 alpha genes in human primary liver tumors with beta-catenin mutations. Oncogene; 2006 Jan 26;25(4):599-608
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Overexpression of regenerating islet-derived 1 alpha and 3 alpha genes in human primary liver tumors with beta-catenin mutations.
  • The Wnt/beta-catenin signaling pathway is activated in many human hepatocellular carcinomas (HCC).
  • They encode the Regenerating islet-derived 3 alpha (REG3A/HIP/PAP/REG-III) and 1 alpha (REG1A) proteins, both involved in liver and pancreatic regeneration and proliferation.
  • Using siRNA directed against beta-catenin, we demonstrated that REG3A is a target of beta-catenin signaling in Huh7 hepatoma cells.
  • Thus, we report strong evidence that both genes are downstream targets of the Wnt pathway during liver tumorigenesis.
  • [MeSH-major] Antigens, Neoplasm / genetics. Biomarkers, Tumor / genetics. Carcinoma, Hepatocellular / genetics. Gene Expression Regulation, Neoplastic. Lectins, C-Type / genetics. Lithostathine / genetics. Liver Neoplasms / genetics. Mutation. beta Catenin / genetics
  • [MeSH-minor] Adenoma / genetics. Adult. Cell Line, Tumor. Colonic Neoplasms / genetics. Hepatoblastoma / genetics. Humans. Male. Signal Transduction

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16314847.001).
  • [ISSN] 0950-9232
  • [Journal-full-title] Oncogene
  • [ISO-abbreviation] Oncogene
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; 0 / Lectins, C-Type; 0 / Lithostathine; 0 / REG1A protein, human; 0 / beta Catenin; 0 / pancreatitis-associated protein
  •  go-up   go-down


30. Phillips A, Hood SR, Gibson GG, Plant NJ: Impact of transcription factor profile and chromatin conformation on human hepatocyte CYP3A gene expression. Drug Metab Dispos; 2005 Feb;33(2):233-42
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Recent data have made it increasingly clear that the gene expression profile of a cell system, and its alteration in response to external stimuli, is highly dependent on both the higher order chromatin structure of the genome and the interaction of gene products in interpreting stimuli.
  • To further explore this phenomenon, we have examined the role of both of these factors in controlling xenobiotic-mediated gene expression changes in primary and transformed human hepatocytes (HuH7).
  • Using quantitative polymerase chain reaction, expression levels of several transcription factors implicated in the liver-specific regulation of the CYP3A gene family were examined in human adult and fetal liver RNA samples.
  • These expression profiles were then compared with those obtained from both primary and transformed human hepatocytes, showing that, in general, cultured cells exhibit a distinct profile compared with either the fetal or adult samples.
  • Whereas exposure to these compounds elicited a dose-dependent increase in CYP3A transcription in primary hepatocytes, no alteration in expression levels was observed for the hepatoma cell line HuH7.
  • Alteration in the expression levels of pregnane X receptor and chicken ovalbumin upstream promoter transcription factor I, and the disruption of higher order chromatin within HuH7 cells altered CYP3A expression and/or activation by xenobiotics toward that observed in primary hepatocytes.
  • [MeSH-minor] Adult. Aged. Cell Line. Cytochrome P-450 CYP3A. Female. Fetus / enzymology. Humans. Male. Middle Aged. Protein Conformation

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15523048.001).
  • [ISSN] 0090-9556
  • [Journal-full-title] Drug metabolism and disposition: the biological fate of chemicals
  • [ISO-abbreviation] Drug Metab. Dispos.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Chromatin; 0 / Transcription Factors; EC 1.14.14.1 / Aryl Hydrocarbon Hydroxylases; EC 1.14.14.1 / Cytochrome P-450 CYP3A; EC 1.5.- / Oxidoreductases, N-Demethylating
  •  go-up   go-down


31. Wong LL, Limm W, Cheung A, Noguchi H: Liver transplant in Hawaii: the survival of a small centre. Clin Transplant; 2006 Jan-Feb;20(1):55-61
MedlinePlus Health Information. consumer health - Liver Transplantation.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Liver transplant in Hawaii: the survival of a small centre.
  • Although many report the importance of case volume in complex cases, liver transplantation (LT) can be carried out successfully in a small centre.
  • Indications for LT were primarily hepatitis C (n = 49) and hepatitis B (n = 13) and 22 patients (25%) had hepatocellular cancer (HCC) on explanted liver.
  • There was no primary graft nonfunction, one retransplant for recurrent hepatitis C and two late hepatic artery thromboses, which did not require a retransplant.
  • During this time period, 142 liver resections, 77 pancreatic resections and 43 splenorenal shunts were performed by this group of surgeons.
  • [MeSH-major] Liver Transplantation / statistics & numerical data
  • [MeSH-minor] Adolescent. Adult. Female. Hawaii. Hepatitis B / surgery. Hepatitis C / surgery. Humans. Male. Middle Aged. Quality of Health Care. Retrospective Studies. Treatment Outcome

  • Genetic Alliance. consumer health - Liver Transplant.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16556154.001).
  • [ISSN] 0902-0063
  • [Journal-full-title] Clinical transplantation
  • [ISO-abbreviation] Clin Transplant
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Denmark
  •  go-up   go-down


32. Guguen-Guillouzo C, Corlu A, Guillouzo A: Stem cell-derived hepatocytes and their use in toxicology. Toxicology; 2010 Mar 30;270(1):3-9
MedlinePlus Health Information. consumer health - Stem Cells.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Stem cell-derived hepatocytes and their use in toxicology.
  • Besides primary hepatocytes and transformed liver cell lines, stem cells either isolated from embryos or adult tissues or obtained by reprogramming somatic cells are emerging as a new potential source of unlimited numbers of hepatocytes.
  • Presently, only hepatocyte-like cells expressing low levels of liver-specific markers, especially drug metabolizing and detoxifying enzymes, are usually obtained, making them still unsuitable as metabolically competent cells for toxicity studies.
  • The only exceptions are some hepatoma cell lines, particularly the HepaRG cell line that can differentiate from a bipotent progenitor stage to attain the functional capacity of normal adult hepatocytes in primary culture without losing the indefinite growth property of transformed cells.
  • [MeSH-minor] Adult. Animals. Cell Line, Tumor. Embryonic Stem Cells / drug effects. Female. Humans. Hybrid Cells. Liver / pathology. Liver Neoplasms / pathology. Pregnancy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2009 Elsevier Ireland Ltd. All rights reserved.
  • (PMID = 19815049.001).
  • [ISSN] 1879-3185
  • [Journal-full-title] Toxicology
  • [ISO-abbreviation] Toxicology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Ireland
  • [Number-of-references] 60
  •  go-up   go-down


33. Naiki T, Nagaki M, Asano T, Kimata T, Moriwaki H: Adenovirus-mediated hepatocyte nuclear factor-4alpha overexpression maintains liver phenotype in cultured rat hepatocytes. Biochem Biophys Res Commun; 2005 Sep 23;335(2):496-500
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adenovirus-mediated hepatocyte nuclear factor-4alpha overexpression maintains liver phenotype in cultured rat hepatocytes.
  • Hepatocyte nuclear factor 4alpha (HNF-4alpha) is a transcription factor that controls embryonal liver development and that maintains and regulates gene expression in adult liver cells.
  • We have previously demonstrated that transient overexpression of HNF-4alpha up-regulates a number of liver-specific genes in hepatoma cell lines.
  • In this study, we extend these studies by assessing the functional role of HNF-4alpha in regulating cellular viability and liver-specific functions of primary rat hepatocytes.
  • In cells transfected with an adenovirus vector carrying rat HNF-4alpha cDNA, induction and maintenance of liver-specific genes and functions were observed over a long-term culture, which might be associated with the prevention of a rapid loss of the mitochondrial membrane potential.
  • In addition, we demonstrated that transthyretin mRNA was up-regulated by HNF-4alpha in primary hepatocytes, but not in hepatoma cells.
  • These results indicate that HNF-4alpha plays a role in the maintenance of morphologically and biochemically functional hepatocytes and that the difference in expression of liver-specific genes induced by HNF-4alpha may depend on a differentiation state of cells.
  • [MeSH-major] Adenoviridae / genetics. DNA-Binding Proteins / metabolism. Gene Expression Regulation. Liver / pathology. Phosphoproteins / metabolism. Transcription Factors / metabolism
  • [MeSH-minor] Ammonia / chemistry. Ammonia / pharmacology. Animals. Blotting, Northern. Cell Differentiation. Cell Survival. DNA, Complementary / metabolism. Genetic Vectors. Gentian Violet / pharmacology. Hepatocyte Nuclear Factor 4. Hepatocytes / cytology. Hepatocytes / metabolism. Intracellular Membranes / metabolism. Male. Membrane Potentials. Microscopy, Phase-Contrast. Mitochondria / metabolism. Phenotype. Rats. Rats, Wistar. Time Factors. Transcription, Genetic. Up-Regulation. beta-Galactosidase / metabolism

  • Hazardous Substances Data Bank. Gentian Violet .
  • Hazardous Substances Data Bank. Ammonia .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16087161.001).
  • [ISSN] 0006-291X
  • [Journal-full-title] Biochemical and biophysical research communications
  • [ISO-abbreviation] Biochem. Biophys. Res. Commun.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA, Complementary; 0 / DNA-Binding Proteins; 0 / Hepatocyte Nuclear Factor 4; 0 / Phosphoproteins; 0 / Transcription Factors; 7664-41-7 / Ammonia; EC 3.2.1.23 / beta-Galactosidase; J4Z741D6O5 / Gentian Violet
  •  go-up   go-down


34. Gondeau C, Pichard-Garcia L, Maurel P: Cellular models for the screening and development of anti-hepatitis C virus agents. Pharmacol Ther; 2009 Oct;124(1):1-22
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Many different models based on different forms of virions and hepatoma or other cell types have been described including virus-like particles, pseudotyped particles, subgenomic and full length replicons, virion productive replicons, immortalised hepatocytes, fetal and adult primary human hepatocytes.
  • This review focuses on these different cellular models, their advantages and disadvantages at the biological and experimental levels, and their respective use for evaluating the effect of antiviral molecules on different steps of HCV biology including virus entry, replication, particles generation and excretion, as well as on the modulation by the virus of the host cell response to infection.

  • Genetic Alliance. consumer health - Hepatitis.
  • HAL archives ouvertes. Full text from .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19555718.001).
  • [ISSN] 1879-016X
  • [Journal-full-title] Pharmacology & therapeutics
  • [ISO-abbreviation] Pharmacol. Ther.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antiviral Agents; 0 / RNA, Viral; 0 / Viral Hepatitis Vaccines
  • [Number-of-references] 337
  •  go-up   go-down


35. Savola S, Klami A, Tripathi A, Niini T, Serra M, Picci P, Kaski S, Zambelli D, Scotlandi K, Knuutila S: Combined use of expression and CGH arrays pinpoints novel candidate genes in Ewing sarcoma family of tumors. BMC Cancer; 2009;9:17
Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Cumulative event free survival (ESFT) and overall survival (OS) were significantly better (P < 0.05) for primary tumors with three or less copy number changes than for tumors with higher number of copy number aberrations.
  • [MeSH-minor] Adolescent. Child. Chromosomes, Human, Pair 11 / genetics. Chromosomes, Human, Pair 20 / genetics. Chromosomes, Human, Pair 21 / genetics. Chromosomes, Human, Pair 22 / genetics. Disease-Free Survival. Humans. Kaplan-Meier Estimate. Repressor Proteins / metabolism. Reverse Transcriptase Polymerase Chain Reaction. Survival Rate. Young Adult

  • Genetic Alliance. consumer health - Ewing's Sarcoma.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2005 Jan 20;23(3):548-58 [15659501.001]
  • [Cites] Cancer Genet Cytogenet. 1999 Oct 1;114(1):35-41 [10526533.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Apr 5;102(14):5138-43 [15790681.001]
  • [Cites] J Pediatr Hematol Oncol. 2005 Apr;27(4):215-8 [15838394.001]
  • [Cites] Oncol Rep. 2005 Jun;13(6):1075-80 [15870924.001]
  • [Cites] Biotechnol Lett. 2005 May;27(9):623-8 [15977068.001]
  • [Cites] J Bone Miner Res. 2005 Sep;20(9):1637-46 [16059635.001]
  • [Cites] J Biol Chem. 2005 Dec 16;280(50):41289-97 [16221674.001]
  • [Cites] Clin Cancer Res. 2006 Jan 1;12(1):117-22 [16397032.001]
  • [Cites] Ann Surg Oncol. 2006 Feb;13(2):159-67 [16411141.001]
  • [Cites] Clin Cancer Res. 2006 Oct 15;12(20 Pt 1):6043-8 [17062679.001]
  • [Cites] Cancer Genet Cytogenet. 2007 Jan 1;172(1):12-22 [17175374.001]
  • [Cites] Traffic. 2007 Mar;8(3):270-84 [17274799.001]
  • [Cites] Biochem Biophys Res Commun. 2007 Jul 13;358(4):1034-40 [17521611.001]
  • [Cites] Int J Cancer. 2007 Sep 1;121(5):1059-65 [17487837.001]
  • [Cites] Ann Oncol. 2007 Dec;18(12):2037-40 [17962210.001]
  • [Cites] Cytogenet Genome Res. 2007;119(1-2):21-6 [18160777.001]
  • [Cites] Nucleic Acids Res. 2008 Jan;36(Database issue):D830-5 [17932056.001]
  • [Cites] Oncogene. 2008 Mar 27;27(14):2084-90 [17952124.001]
  • [Cites] Am J Hum Genet. 2008 Apr;82(4):822-33 [18358451.001]
  • [Cites] Leuk Res. 2008 Aug;32(8):1228-35 [18328560.001]
  • [Cites] Int J Cancer. 2008 Aug 15;123(4):817-25 [18506690.001]
  • [Cites] J Cell Sci. 2008 Nov 1;121(Pt 21):3541-52 [18840648.001]
  • [Cites] Hum Mol Genet. 2009 Jan 15;18(2):341-6 [18923002.001]
  • [Cites] Cancer Genet Cytogenet. 2000 Nov;123(1):1-26 [11120329.001]
  • [Cites] Cancer. 2001 Jun 1;91(11):2156-64 [11391597.001]
  • [Cites] Genes Chromosomes Cancer. 2001 Oct;32(2):164-71 [11550284.001]
  • [Cites] J Biol Chem. 2001 Oct 5;276(40):37564-8 [11481329.001]
  • [Cites] Cancer Genet Cytogenet. 2001 Oct 1;130(1):57-61 [11672775.001]
  • [Cites] Bioinformatics. 2001 Dec;17(12):1228-9 [11751233.001]
  • [Cites] Methods. 2001 Dec;25(4):402-8 [11846609.001]
  • [Cites] Cancer Genet Cytogenet. 2002 Feb;133(1):102-3 [11891000.001]
  • [Cites] J Biol Chem. 2002 Mar 22;277(12):10315-22 [11751870.001]
  • [Cites] World J Gastroenterol. 2001 Aug;7(4):551-4 [11819827.001]
  • [Cites] Br J Cancer. 2002 Jun 5;86(11):1763-9 [12087464.001]
  • [Cites] J Clin Pathol. 2003 Feb;56(2):96-102 [12560386.001]
  • [Cites] Cancer Genet Cytogenet. 2003 Jan 15;140(2):107-12 [12645647.001]
  • [Cites] Genes Chromosomes Cancer. 2003 May;37(1):1-19 [12661001.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Aug 5;100(16):9440-5 [12883005.001]
  • [Cites] J Biol Chem. 2003 Aug 22;278(34):31564-73 [12771153.001]
  • [Cites] J Biol Chem. 2003 Sep 19;278(38):36707-17 [12853457.001]
  • [Cites] J Clin Oncol. 2004 Aug 15;22(16):3230-7 [15310766.001]
  • [Cites] Nat Genet. 2004 Oct;36(10):1084-9 [15361874.001]
  • [Cites] Biochem Biophys Res Commun. 2004 Nov 12;324(2):554-61 [15474462.001]
  • [Cites] Nature. 1992 Sep 10;359(6391):162-5 [1522903.001]
  • [Cites] Genomics. 1992 Dec;14(4):1092-4 [1335957.001]
  • [Cites] Genes Chromosomes Cancer. 1996 Sep;17(1):7-13 [8889501.001]
  • [Cites] Br J Cancer. 1997;75(10):1403-9 [9166930.001]
  • [Cites] Cancer. 1999 Aug 1;86(3):421-8 [10430250.001]
  • [Cites] Genes Chromosomes Cancer. 1999 Mar;24(3):243-54 [10451705.001]
  • [Cites] Cancer Res. 2005 Feb 1;65(3):925-32 [15705892.001]
  • (PMID = 19144156.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Validation Studies
  • [Publication-country] England
  • [Chemical-registry-number] 0 / ANKRD11 protein, human; 0 / Calmodulin-Binding Proteins; 0 / EWSR1 protein, human; 0 / Intercellular Signaling Peptides and Proteins; 0 / RNA-Binding Proteins; 0 / Repressor Proteins; 0 / hepatoma-derived growth factor
  • [Other-IDs] NLM/ PMC2633345
  •  go-up   go-down


36. Zhao W, Liu H, Liu W, Wu Y, Chen W, Jiang B, Zhou Y, Xue R, Luo C, Wang L, Jiang JD, Liu J: Abnormal activation of the synuclein-gamma gene in hepatocellular carcinomas by epigenetic alteration. Int J Oncol; 2006 May;28(5):1081-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Abnormal activation of the synuclein-gamma gene in hepatocellular carcinomas by epigenetic alteration.
  • Liver cancer is the fifth most common neoplastic disease and the fourth leading cause of cancer-related death.
  • In this study, by conducting immunohistochemistry, we show that the neuronal protein, synuclein-gamma (SNCG), is abnormally expressed in a high percentage of liver cancer (46/70, 65.7%).
  • The expression of SNCG in liver cancer exhibits a clear stage-specific pattern of low expression in stage I (1/19, 5.3%) and high expression in stages III to IV (44/50, 88%).
  • Importantly, all patients with metastatic diseases expressed SNCG in their primary tumors (15/15, 100%).
  • Consistent with the IHC results, RT-PCR assays demonstrate that SNCG mRNA is highly expressed in the tumor tissue of advanced hepatocellular carcinomas.
  • To determine whether demethylation of SNCG is an early event of genetic abnormality in the process of hepatocarcinogenesis, we examined the methylation status of SNCG in 70 non-malignant cirrhotic liver samples and showed that 64.3% cirrhotic liver samples contained the partially or completely demethylated gene.
  • We further show that SNCG expression in liver cancer is not restricted to HBV- and HCV-infected tumors, implying the involvement of other hepatocarcinogenic risk factors in SNCG gene reactivation.
  • Utilizing human hepatoma-derived cell line HepG2 as an in vitro model, we demonstrate that hepatic carcinogens aflatoxin B1 and N-nitrosodimethylamine (DMN) are strong inducers of SNCG expression.
  • Collectively, these new findings suggest that SNCG protein expression in primary tumors is a strong indicator of distant metastasis and demethylation of SNCG CpG island is an early sign of genetic abnormality in liver cirrhosis preceding hepatocarcinogenesis.
  • [MeSH-major] Carcinoma, Hepatocellular / genetics. Epigenesis, Genetic / genetics. Gene Expression Regulation, Neoplastic. Liver Neoplasms / genetics. gamma-Synuclein / genetics
  • [MeSH-minor] Adult. Azacitidine / pharmacology. Base Sequence. Cell Line, Tumor. DNA Methylation. Female. Humans. Lymphatic Metastasis. Male. Middle Aged. Molecular Sequence Data. Neoplasm Metastasis. Neoplasm Proteins / genetics. Neoplasm Staging

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • Hazardous Substances Data Bank. AZACITIDINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16596223.001).
  • [ISSN] 1019-6439
  • [Journal-full-title] International journal of oncology
  • [ISO-abbreviation] Int. J. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Neoplasm Proteins; 0 / SNCG protein, human; 0 / gamma-Synuclein; M801H13NRU / Azacitidine
  •  go-up   go-down


37. Hu TH, Huang CC, Wu CL, Lin PR, Liu SY, Lin JW, Chuang JH, Tai MH: Increased endostatin/collagen XVIII expression correlates with elevated VEGF level and poor prognosis in hepatocellular carcinoma. Mod Pathol; 2005 May;18(5):663-72
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Increased endostatin/collagen XVIII expression correlates with elevated VEGF level and poor prognosis in hepatocellular carcinoma.
  • Liver is the primary source for collagen XVIII, the precursor of angiogenesis inhibitor, endostatin.
  • However, the role of endostatin/collagen XVIII expression during liver carcinogenesis remains elusive.
  • Therefore, we studied its expression in five hepatoma cell lines and 105 hepatocellular carcinoma specimens.
  • The poorly differentiated hepatoma cell lines exhibited increased endostatin/collagen XVIII levels compared with the well-differentiated ones.
  • In hepatoma tissues, endostatin/collagen XVIII expression was detected in various types of liver cells and was significantly stronger in adjacent nontumor tissues than that in tumors (P<0.001).
  • In conclusion, increased endostatin/collagen XVIII expression correlated with hepatoma progression and predicted poor prognosis for patients with hepatocellular carcinoma.
  • [MeSH-major] Carcinoma, Hepatocellular / pathology. Collagen Type XVIII / genetics. Endostatins / genetics. Liver Neoplasms / pathology. Vascular Endothelial Growth Factor A / metabolism
  • [MeSH-minor] Adult. Aged. Cell Line, Tumor. Female. Gene Expression Profiling. Gene Expression Regulation, Neoplastic. HeLa Cells. Humans. Immunohistochemistry. Male. Middle Aged. Multivariate Analysis. Neoplasm Recurrence, Local. Neoplasm Staging. Prognosis. RNA, Neoplasm / genetics. RNA, Neoplasm / metabolism. Reverse Transcriptase Polymerase Chain Reaction / methods. Survival Analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15605080.001).
  • [ISSN] 0893-3952
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Collagen Type XVIII; 0 / Endostatins; 0 / RNA, Neoplasm; 0 / Vascular Endothelial Growth Factor A
  •  go-up   go-down


38. Kou T, Marusawa H, Kinoshita K, Endo Y, Okazaki IM, Ueda Y, Kodama Y, Haga H, Ikai I, Chiba T: Expression of activation-induced cytidine deaminase in human hepatocytes during hepatocarcinogenesis. Int J Cancer; 2007 Feb 1;120(3):469-76
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Activation-induced cytidine deaminase (AID) plays a role as a genome mutator in activated B cells, and inappropriate expression of AID has been implicated in the immunopathological phenotype of human B-cell malignancies.
  • Notably, we found that the transgenic mice overexpressing AID developed lung adenocarcinoma and hepatocellular carcinoma (HCC), suggesting that ectopic expression of AID can lead to tumorigenesis in epithelial tissues as well.
  • To examine the involvement of AID in the development of human HCC, we analyzed the AID expression and its correlation with mutation frequencies of the p53 gene in liver tissues from 51 patients who underwent resection of primary HCCs.
  • Only trace amounts of AID transcripts were detected in the normal liver; however, endogenous AID was significantly upregulated in both HCC and surrounding noncancerous liver tissues with underlying chronic hepatitis or liver cirrhosis (p < 0.05).
  • Most liver tissues with underlying chronic inflammation with endogenous AID upregulation already contained multiple genetic changes in the p53 gene.
  • In both hepatoma cell lines and cultured human primary hepatocytes, the expression of AID was substantially induced by TGF-beta stimulation.
  • Our findings suggest that the aberrant expression of AID is observed in human hepatocytes with several pathological settings, including chronic liver disease and HCC, which might enhance the genetic susceptibility to mutagenesis leading to hepatocarcinogenesis.
  • [MeSH-major] Carcinoma, Hepatocellular / genetics. Cytidine Deaminase / genetics. Hepatocytes / metabolism. Liver Neoplasms / genetics
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Amino Acid Sequence. Base Sequence. Cell Line, Tumor. Cells, Cultured. Enzyme Activation. Female. Gene Expression Regulation, Enzymologic / drug effects. Gene Expression Regulation, Neoplastic / drug effects. Hepatitis, Viral, Human / physiopathology. Humans. Immunoblotting. Male. Middle Aged. Mutation / genetics. RNA, Messenger / genetics. RNA, Messenger / metabolism. Reverse Transcriptase Polymerase Chain Reaction. Transforming Growth Factor beta / pharmacology. Tumor Suppressor Protein p53 / genetics

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17066440.001).
  • [ISSN] 0020-7136
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / RNA, Messenger; 0 / Transforming Growth Factor beta; 0 / Tumor Suppressor Protein p53; EC 3.5.4.5 / Cytidine Deaminase
  •  go-up   go-down


39. Hellerbrand C, Bataille F, Schlegel J, Hartmann A, Mühlbauer M, Schölmerich J, Büttner R, Hofstädter F, Bosserhoff AK: In situ expression patterns of melanoma inhibitory activity 2 in healthy and diseased livers. Liver Int; 2005 Apr;25(2):357-66
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: We analyzed liver tissue of patients with chronic hepatitis C (HepC) infection and hepatocellular carcinoma (HCC) as well as a human multi-tissue array, primary human hepatocytes and the hepatoma cell-lines HepG2, Hep3B and PLC by immunohistochemical staining and quantitative RT-PCR.
  • RESULTS: Hepatocytes were confirmed as the exclusive cellular source of MIA2 expression, with a granular, cytoplasmatic staining pattern without enhancement at the cell membrane.
  • In contrast, only low MIA2 expression levels were detected in most HCC and hepatoma cell lines.
  • Interestingly, both in HCC and liver tissues of patients with HepC we found a correlation of MIA2 and alpha-sma expression.
  • [MeSH-major] Carcinoma, Hepatocellular / pathology. Hepatitis, Chronic / pathology. Liver Cirrhosis / pathology. Liver Neoplasms / pathology. Neoplasm Proteins / metabolism
  • [MeSH-minor] Adult. Base Sequence. Biomarkers / analysis. Biopsy, Needle. Case-Control Studies. Extracellular Matrix Proteins. Female. Gene Expression Regulation, Neoplastic. Hepatocytes / metabolism. Humans. Immunohistochemistry. Male. Middle Aged. Molecular Sequence Data. Prognosis. RNA, Neoplasm / analysis. RNA, Viral / analysis. Reference Values. Reverse Transcriptase Polymerase Chain Reaction. Sensitivity and Specificity. Tissue Culture Techniques

  • MedlinePlus Health Information. consumer health - Cirrhosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright Blackwell Munksgaard 2005
  • (PMID = 15780062.001).
  • [ISSN] 1478-3223
  • [Journal-full-title] Liver international : official journal of the International Association for the Study of the Liver
  • [ISO-abbreviation] Liver Int.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers; 0 / Extracellular Matrix Proteins; 0 / MIA protein, human; 0 / Neoplasm Proteins; 0 / RNA, Neoplasm; 0 / RNA, Viral
  •  go-up   go-down


40. Pichard-Garcia L, Briolotti P, Larrey D, Sa-Cunha A, Suc B, Laporte S, Maurel P: Use of human hepatocytes to investigate HCV infection. Methods Mol Biol; 2010;640:447-62
MedlinePlus Health Information. consumer health - Hepatitis C.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Different systems have been constructed based on hepatoma or other cell lines, sub-genomic and genomic replicons, productive replicons, and immortalized hepatocytes.
  • Adult primary human hepatocytes infected with natural serum-derived HCV virions represent the model that most closely mimics the physiological situation.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20645067.001).
  • [ISSN] 1940-6029
  • [Journal-full-title] Methods in molecular biology (Clifton, N.J.)
  • [ISO-abbreviation] Methods Mol. Biol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 9008-11-1 / Interferons
  •  go-up   go-down


41. Modanlou KA, Oliver DA, Grossman BJ: Liver donor's age and recipient's serum creatinine predict blood component use during liver transplantation. Transfusion; 2009 Dec;49(12):2645-51
MedlinePlus Health Information. consumer health - Organ Donation.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Liver donor's age and recipient's serum creatinine predict blood component use during liver transplantation.
  • BACKGROUND: Excessive use of blood components during liver transplantation should be avoided because it has been associated with poor outcomes and it may stress blood bank resources.
  • STUDY DESIGN AND METHODS: To determine preoperative predictors of excessive transfusion requirements in patients undergoing liver transplantation, the clinical records of 126 consecutive adult patients undergoing primary liver transplantation were retrospectively reviewed.
  • Univariate analyses of the following predictor variables were performed: recipient age, sex, ethnicity, height/weight, Model for End Stage Liver Disease score, year of transplant, previous abdominal surgery, hepatoma, wait-list time, standard recipient laboratory values obtained immediately before transplantation, cold ischemia time, donor age, sex, and height/weight.
  • ] CONCLUSION: Liver donor's age and recipient's SCr are important in preoperatively predicting blood use during liver transplantation.
  • [MeSH-major] Blood Component Transfusion. Blood Loss, Surgical / prevention & control. Creatinine / blood. Liver Transplantation. Tissue Donors
  • [MeSH-minor] Adult. Age Factors. Aged. Blood Banks. Erythrocyte Count. Female. Humans. Logistic Models. Male. Middle Aged. Multivariate Analysis. Predictive Value of Tests. Preoperative Care. Retrospective Studies

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Creatinine.
  • MedlinePlus Health Information. consumer health - Liver Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19682344.001).
  • [ISSN] 1537-2995
  • [Journal-full-title] Transfusion
  • [ISO-abbreviation] Transfusion
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] AYI8EX34EU / Creatinine
  •  go-up   go-down


42. Alali J, Ramji A, Ho JK, Scudamore CH, Erb SR, Cheung E, Kopit B, Bannon CA, Chung SW, Soos JG, Buczkowski AK, Brooks EM, Steinbrecher UP, Yoshida EM: Liver transplant candidacy unsuitability: a review of the British Columbia experience. Can J Gastroenterol; 2006 Feb;20(2):95-9
MedlinePlus Health Information. consumer health - Liver Transplantation.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Liver transplant candidacy unsuitability: a review of the British Columbia experience.
  • BACKGROUND: Every centre has contraindications to liver transplantation and declares patients unsuitable for medical or nonmedical reasons.
  • METHODS: A retrospective chart review was completed from 1997 to 2001, inclusive of all patients referred for liver transplant to the British Columbia Transplant Society who were declared unsuitable for transplantation, as well as the reasons for unsuitability.
  • The most common primary liver disease was hepatitis C (n=53, 35%), followed by alcoholic liver disease (n=35, 24%) and autoimmune liver diseases (n=23, 16%).
  • Medical contraindications constituted 74 patients (49.0%) and the most common reasons for unsuitability were no need of a liver transplant (29 patients [39%]), exclusion due to hepatoma or extrahepatic malignancy (20 patients [27%]) and multisystem failure (12 patients [16%]).
  • [MeSH-major] Liver Diseases / surgery. Liver Transplantation / contraindications. Patient Selection
  • [MeSH-minor] Adolescent. Adult. Aged. British Columbia. Comorbidity. Female. Hepatitis C / surgery. Humans. Liver Diseases, Alcoholic / epidemiology. Liver Diseases, Alcoholic / surgery. Male. Middle Aged. Social Support

  • Genetic Alliance. consumer health - Liver Transplant.
  • MedlinePlus Health Information. consumer health - Liver Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Liver Transpl. 2000 Jan;6(1):122-35 [10648593.001]
  • [Cites] Transplantation. 2000 Nov 15;70(9):1335-42 [11087149.001]
  • [Cites] Can J Gastroenterol. 2000 Nov;14(10):851-5 [11111107.001]
  • [Cites] Gastroenterology. 2002 Dec;123(6):1839-47 [12454841.001]
  • [Cites] Dig Dis Sci. 1986 May;31(5):468-75 [3009109.001]
  • [Cites] Am J Gastroenterol. 1993 Sep;88(9):1337-42 [8362826.001]
  • [Cites] Clin Liver Dis. 1997 Aug;1(2):247-61, vii [15562567.001]
  • [Cites] N Engl J Med. 1996 Mar 14;334(11):693-9 [8594428.001]
  • [Cites] Liver Transpl Surg. 1996 Mar;2(2):148-53 [9346641.001]
  • [Cites] Can J Gastroenterol. 1998 Apr;12(3):209-15 [9582546.001]
  • [Cites] Transplantation. 1999 Jun 27;67(12):1562-8 [10401763.001]
  • [Cites] Gut. 1999 Sep;45(3):421-6 [10446113.001]
  • [Cites] Hepatology. 1995 Jan;21(1):140-4 [7806148.001]
  • (PMID = 16482235.001).
  • [ISSN] 0835-7900
  • [Journal-full-title] Canadian journal of gastroenterology = Journal canadien de gastroenterologie
  • [ISO-abbreviation] Can. J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Canada
  • [Other-IDs] NLM/ PMC2538970
  •  go-up   go-down


43. Wang GL, Wang MY, Wei WB: [Clinical features and treatment of choroidal metastasis]. Zhonghua Yan Ke Za Zhi; 2009 Mar;45(3):229-33

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Primary tumours were found in 40 cases (81.6%) (surgical excision in 25 cases), consisting of breast carcinoma in 16 cases (32.7%), lung carcinoma in 14 cases (28.6%), hepatoma and cholangiocarcinoma in 3 cases, colon and stomach carcinomas in 3 cases, gynecologic appendix carcinoma (including 1 case of ovarian mucous cyst adenocarcinoma) in 2 cases, nasopharyngeal adenocarcinoma in 1 case, vertebra tumor in 1 case, undetected in 5 cases (10.2%) and under detection in 4 cases (8.2%).
  • The primary tumor can be found in 80% of cases.
  • The most common primary cancer is breast carcinoma, followed by lung carcinoma.
  • These two cancers account for 75% of primary tumors.
  • [MeSH-minor] Adult. Aged. Female. Fluorescein Angiography. Fundus Oculi. Humans. Male. Middle Aged. Neoplasm Metastasis. Retrospective Studies. Treatment Outcome. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19575917.001).
  • [ISSN] 0412-4081
  • [Journal-full-title] [Zhonghua yan ke za zhi] Chinese journal of ophthalmology
  • [ISO-abbreviation] Zhonghua Yan Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


44. Kolkhof P, Geerts A, Schäfer S, Torzewski J: Cardiac glycosides potently inhibit C-reactive protein synthesis in human hepatocytes. Biochem Biophys Res Commun; 2010 Mar 26;394(1):233-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We show here that endogenous and plant-derived inhibitors of the Na(+)/K(+)-ATPase, i.e. the cardiac glycosides ouabain and digitoxin, inhibit IL-1beta- and IL-6-induced APP expression in human hepatoma cells and primary human hepatocytes (PHH) at nanomolar concentrations.
  • Qualified specificity of oubain for hepatocellular APP synthesis inhibition is demonstrated by lack of effectivity on IL-1beta-induced IL-6 release from primary human coronary artery smooth muscle cells.
  • [MeSH-minor] Adult. Calcium / metabolism. Cell Line, Tumor. Cells, Cultured. Digitoxin / pharmacology. Female. Humans. Interleukin-1beta / pharmacology. Interleukin-6 / pharmacology. Male. Middle Aged. Ouabain / pharmacology. Promoter Regions, Genetic / drug effects

  • Hazardous Substances Data Bank. OUABAIN .
  • Hazardous Substances Data Bank. DIGITOXIN .
  • Hazardous Substances Data Bank. CALCIUM, ELEMENTAL .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2010 Elsevier Inc. All rights reserved.
  • (PMID = 20206126.001).
  • [ISSN] 1090-2104
  • [Journal-full-title] Biochemical and biophysical research communications
  • [ISO-abbreviation] Biochem. Biophys. Res. Commun.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cardiac Glycosides; 0 / Interleukin-1beta; 0 / Interleukin-6; 5ACL011P69 / Ouabain; 9007-41-4 / C-Reactive Protein; E90NZP2L9U / Digitoxin; SY7Q814VUP / Calcium
  •  go-up   go-down


45. Da Ines D, Petitcolin V, Lannareix V, Montoriol P, Joubert Zakeyh J, Boyer L, Garcier J: [Liver capsule retraction adjacent to a circumscribed liver lesion: review of 26 cases with histological confirmation]. J Radiol; 2009 Sep;90(9 Pt 1):1067-74
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Liver capsule retraction adjacent to a circumscribed liver lesion: review of 26 cases with histological confirmation].
  • PURPOSE: To review the histological features of 26 circumscribed liver lesions associated with liver capsule retraction and discuss the differential diagnosis while evaluating for the presence of fibrous stromal reaction.
  • Retrospective study performed between January 2005 and June 2008 including 26 patients: 18 males and 6 females, without history of cancer, aged between 42 and 82 years (mean age: 64.5 years), presenting with liver capsule retraction adjacent to a circumscribed liver lesion detected on CT or MRI.
  • All liver lesions were biopsied with semi-quantitative evaluation of fibrous stromal reaction.
  • RESULTS: Twenty-one patients had benign or malignant liver tumors and 5 patients had confluent hepatic fibrosis.
  • Twenty of 21 liver tumors were malignant (95.2%): 3 intra-hepatic cholangiocarcinoma, 17 cases of metastatic disease including colorectal carcinoma (n=8), bronchogenic carcinoma (n=1), pancreatic carcinoma (n=4), esophageal carcinoma (n=1), breast carcinoma (n=1), gallbladder carcinoma (1) and endocrine neoplasm of the pancreas (n=1), and 1 case of liver sclerosing angioma (n=1).
  • There was no case of hepatoma.
  • CONCLUSION: The presence of capsular retraction next to a circumscribed liver lesion, while non-specific, is suspicious.
  • In keeping with previous reports, metastases were frequently the cause and intrahepatic cholangiocarcinoma was the most frequent primary tumor.
  • In patients with chronic hepatocellular disease, confluent fibrosis was a frequent etiology.
  • [MeSH-major] Liver Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Male. Middle Aged. Retrospective Studies

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Radiol. 2009 Sep;90(9 Pt 1):1019-20 [19752803.001]
  • (PMID = 19752810.001).
  • [ISSN] 0221-0363
  • [Journal-full-title] Journal de radiologie
  • [ISO-abbreviation] J Radiol
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


46. Li Y, Tan T, Mo T, Lu W, Deng H, Yang X, Li X: [Pharmacokinetics of injection of iodine-131 labelling MEI-TUO-XI monoclonal antibody in human body]. Sheng Wu Yi Xue Gong Cheng Xue Za Zhi; 2007 Aug;24(4):857-61
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • To study pharmacokinetics of injection of iodine-131 labelling MEI-TUO-XI monoclonal antibody (hepatoma monoclonal antibody HAb18 F(ab')2) in vivo.
  • 24 cases of primary hepatocelluar carcinoma (PHC) were equally divided into the low dose group, middle dose group and high dose group.
  • [MeSH-major] Antibodies, Monoclonal / pharmacokinetics. Drug Delivery Systems. Iodine Radioisotopes / pharmacokinetics. Liver Neoplasms / radiotherapy
  • [MeSH-minor] Adolescent. Adult. Aged. Antibodies, Neoplasm / immunology. Female. Hepatic Artery. Humans. Immunoglobulin Fab Fragments. Injections, Intra-Arterial. Male. Middle Aged. Radioimmunotherapy. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17899760.001).
  • [ISSN] 1001-5515
  • [Journal-full-title] Sheng wu yi xue gong cheng xue za zhi = Journal of biomedical engineering = Shengwu yixue gongchengxue zazhi
  • [ISO-abbreviation] Sheng Wu Yi Xue Gong Cheng Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Neoplasm; 0 / Immunoglobulin Fab Fragments; 0 / Iodine Radioisotopes
  •  go-up   go-down


47. Guguen-Guillouzo C, Guillouzo A: General review on in vitro hepatocyte models and their applications. Methods Mol Biol; 2010;640:1-40

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Primary hepatocytes appear as the closest model for the liver in vivo.
  • Hepatoma cell lines appear as an alternative but only the HepaRG cell line exhibits various functions, including major cytochrome P450 activities, at levels close to those found in primary hepatocytes.
  • In vitro hepatocyte models have brought a substantial contribution to the understanding of the biochemistry, physiology, and cell biology of the normal and diseased liver and in various application domains such as xenobiotic metabolism and toxicity, virology, parasitology, and more generally cell therapies.
  • In the future, new well-differentiated hepatocyte cell lines derived from tumors or from either embryonic or adult stem cells might be expected and although hepatocytes will continue to be used in various fields, these in vitro liver models should allow marked advances, especially in cell-based therapies and predictive and mechanistic hepatotoxicity of new drugs and other chemicals.
  • All models will benefit from new developments in throughput screening based on cell chips coupled with high-content imaging and in toxicogenomics technologies.
  • [MeSH-minor] Animals. Cell Culture Techniques / methods. Humans. Models, Biological. Toxicogenetics. Xenobiotics / metabolism. Xenobiotics / toxicity

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20645044.001).
  • [ISSN] 1940-6029
  • [Journal-full-title] Methods in molecular biology (Clifton, N.J.)
  • [ISO-abbreviation] Methods Mol. Biol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Xenobiotics
  •  go-up   go-down


48. Kersten S, Lichtenstein L, Steenbergen E, Mudde K, Hendriks HF, Hesselink MK, Schrauwen P, Müller M: Caloric restriction and exercise increase plasma ANGPTL4 levels in humans via elevated free fatty acids. Arterioscler Thromb Vasc Biol; 2009 Jun;29(6):969-74
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Fatty acids markedly induced ANGPTL4 gene expression in rat hepatoma FAO cells, human primary myocytes, and mouse intestinal MSIE cells.
  • [MeSH-minor] Adrenergic beta-Agonists / administration & dosage. Adult. Albuterol / administration & dosage. Animals. Cells, Cultured. Enzyme-Linked Immunosorbent Assay. Fat Emulsions, Intravenous / administration & dosage. Humans. Hypolipidemic Agents / administration & dosage. Intestines / metabolism. Liver Neoplasms / metabolism. Male. Mice. Middle Aged. Myocytes, Cardiac / metabolism. RNA, Messenger / metabolism. Rats. Time Factors. Transfection. Up-Regulation. Young Adult

  • MedlinePlus Health Information. consumer health - Exercise and Physical Fitness.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. ALBUTEROL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19342599.001).
  • [ISSN] 1524-4636
  • [Journal-full-title] Arteriosclerosis, thrombosis, and vascular biology
  • [ISO-abbreviation] Arterioscler. Thromb. Vasc. Biol.
  • [Language] eng
  • [Publication-type] Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / ANGPTL4 protein, human; 0 / ANGPTL4 protein, rat; 0 / Adrenergic beta-Agonists; 0 / Angiopoietins; 0 / Angptl4 protein, mouse; 0 / Fat Emulsions, Intravenous; 0 / Fatty Acids, Nonesterified; 0 / Hypolipidemic Agents; 0 / RNA, Messenger; QF8SVZ843E / Albuterol
  •  go-up   go-down


49. Mizgireuv IV, Revskoy SY: Transplantable tumor lines generated in clonal zebrafish. Cancer Res; 2006 Mar 15;66(6):3120-5
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The primary tumors in CB1 fish were induced by N-nitrosodiethylamine (DEN).
  • The histologic analysis of these tumors revealed different types of hepatocellular carcinomas, hepatoblastomas, hepatoma, cholangiocarcinoma, and pancreatic carcinoma.
  • Four spontaneous acinar cell carcinomas of pancreas were also found in 10- to 18-month-old CB1 fish.
  • Small pieces of tissue or cell suspensions of either DEN-induced or spontaneous tumors were serially transplanted into the peritoneal cavity of syngeneic fish at different stages of development from 5-day-old larvae to adult fish.
  • [MeSH-minor] Animals. Cell Line, Tumor. Diethylnitrosamine. Diploidy. Disease Models, Animal. Homozygote. Humans. Male. Neoplasm Transplantation

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. N-NITROSODIETHYLAMINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16540662.001).
  • [ISSN] 0008-5472
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 3IQ78TTX1A / Diethylnitrosamine
  •  go-up   go-down


50. Zhong J, Krawczyk SA, Chaerkady R, Huang H, Goel R, Bader JS, Wong GW, Corkey BE, Pandey A: Temporal profiling of the secretome during adipogenesis in humans. J Proteome Res; 2010 Oct 1;9(10):5228-38
antibodies-online. View related products from antibodies-online.com (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We carried out a temporal proteomic analysis to interrogate the dynamic changes in the secretome of primary human preadipocytes as they differentiate into mature adipocytes.
  • They include collagen triple helix repeat containing 1, cytokine receptor-like factor 1, glypican-1, hepatoma-derived growth factor, SPARC related modular calcium binding protein 1, SPOCK 1, and sushi repeat-containing protein.

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nat Biotechnol. 2006 Mar;24(3):333-8 [16525410.001]
  • [Cites] J Proteome Res. 2006 Jul;5(7):1674-81 [16823975.001]
  • [Cites] Cell Metab. 2006 Oct;4(4):263-73 [17011499.001]
  • [Cites] Mol Cell Proteomics. 2007 Jan;6(1):18-28 [17018519.001]
  • [Cites] Mol Cell Proteomics. 2007 Apr;6(4):589-600 [17255083.001]
  • [Cites] Eur J Cancer. 2007 May;43(7):1117-24 [17379503.001]
  • [Cites] Mol Cell Biochem. 2007 Jun;300(1-2):61-7 [17541509.001]
  • [Cites] Endocrinology. 2007 Aug;148(8):3850-62 [17478559.001]
  • [Cites] Prostate. 2007 Sep 1;67(12):1308-17 [17626247.001]
  • [Cites] Horm Metab Res. 2007 Oct;39(10):722-5 [17952833.001]
  • [Cites] Nat Biotechnol. 2008 Feb;26(2):164-7 [18259167.001]
  • [Cites] Proteomics. 2008 Feb;8(3):569-81 [18175373.001]
  • [Cites] Biochem Biophys Res Commun. 2008 May 16;369(4):1204-8 [18343214.001]
  • [Cites] Curr Opin Clin Nutr Metab Care. 2008 May;11(3):208-13 [18403914.001]
  • [Cites] Endocrinol Metab Clin North Am. 2008 Sep;37(3):753-68, x-xi [18775362.001]
  • [Cites] Mol Cell Endocrinol. 2008 Dec 16;296(1-2):32-40 [18801408.001]
  • [Cites] Nucleic Acids Res. 2009 Jan;37(Database issue):D773-81 [18948298.001]
  • [Cites] Nucleic Acids Res. 2009 Jan;37(Database issue):D767-72 [18988627.001]
  • [Cites] J Oral Sci. 2008 Dec;50(4):419-25 [19106469.001]
  • [Cites] J Proteome Res. 2009 Jan;8(1):48-58 [18947249.001]
  • [Cites] Mol Cell Biol. 2009 Mar;29(6):1575-91 [19114551.001]
  • [Cites] Proteomics. 2009 Mar;9(5):1374-84 [19253296.001]
  • [Cites] Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2009 Jul;108(1):e1-7 [19540439.001]
  • [Cites] Curr Med Chem. 2009;16(23):2952-64 [19689276.001]
  • [Cites] Methods Mol Biol. 2009;577:199-214 [19718518.001]
  • [Cites] Int J Obes (Lond). 2009 Sep;33(9):991-1000 [19652659.001]
  • [Cites] Proteomics. 2010 Feb;10(3):394-405 [19953544.001]
  • [Cites] Mol Immunol. 2010 Mar;47(6):1244-54 [20116105.001]
  • [Cites] Mol Cell. 1999 Oct;4(4):585-95 [10549290.001]
  • [Cites] Mol Cell. 1999 Oct;4(4):611-7 [10549292.001]
  • [Cites] Nat Immunol. 2001 Dec;2(12):1133-7 [11694882.001]
  • [Cites] Biomol Eng. 2001 Nov;18(5):195-205 [11911086.001]
  • [Cites] Mol Cell Proteomics. 2002 Mar;1(3):213-22 [12096121.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Sep 16;100(19):10931-6 [12953101.001]
  • [Cites] Eur Cell Mater. 2003 Oct 6;6:12-21; discussion 21 [14562268.001]
  • [Cites] Educ Health (Abingdon). 2003 Jul;16(2):230 [14741909.001]
  • [Cites] Cell Mol Life Sci. 2004 Sep;61(18):2405-17 [15378209.001]
  • [Cites] Cell. 1975 May;5(1):19-27 [165899.001]
  • [Cites] Cell. 1994 Dec 30;79(7):1147-56 [8001151.001]
  • [Cites] Diabetologia. 1995 Jul;38(7):764-71 [7556976.001]
  • [Cites] J Clin Invest. 1996 Jan 1;97(1):37-46 [8550848.001]
  • [Cites] Mol Cell Proteomics. 2004 Dec;3(12):1154-69 [15385600.001]
  • [Cites] J Proteome Res. 2005 Mar-Apr;4(2):570-7 [15822936.001]
  • [Cites] Thromb Haemost. 2005 Apr;93(4):631-40 [15841306.001]
  • [Cites] Ophthalmic Genet. 2005 Jun;26(2):101-5 [16020313.001]
  • [Cites] Mol Cell Proteomics. 2006 Jan;5(1):26-34 [16188874.001]
  • [Cites] J Biol Chem. 2006 Mar 3;281(9):5406-15 [16354654.001]
  • [Cites] Expert Opin Ther Pat. 2010 Apr;20(4):497-506 [20205619.001]
  • [Cites] Nat Rev Endocrinol. 2010 Apr;6(4):225-35 [20195270.001]
  • (PMID = 20707391.001).
  • [ISSN] 1535-3907
  • [Journal-full-title] Journal of proteome research
  • [ISO-abbreviation] J. Proteome Res.
  • [Language] ENG
  • [Grant] United States / NIDDK NIH HHS / DK / R01 DK035914; United States / NCRR NIH HHS / RR / U54 RR020839; United States / NCRR NIH HHS / RR / S10RR023025; United States / NIDDK NIH HHS / DK / P30 DK046200; United States / NIDDK NIH HHS / DK / DK056690; United States / NCRR NIH HHS / RR / U54 RR 020839; United States / NIDDK NIH HHS / DK / P60 DK079637; United States / NIDDK NIH HHS / DK / DK084171; United States / NCRR NIH HHS / RR / S10 RR023025; United States / NIDDK NIH HHS / DK / R01 DK084171; United States / NIDDK NIH HHS / DK / R01 DK056690; United States / NIDDK NIH HHS / DK / DK46200
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Proteome
  • [Other-IDs] NLM/ PMC2948433
  •  go-up   go-down


51. Dong-Dong L: Up-regulation expression of MLC1 in human liver cancer tissue and enhanced SMMC7721 cell tumorigenesis in vivo and vitro. Hepatogastroenterology; 2005 Jul-Aug;52(64):1186-90
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Up-regulation expression of MLC1 in human liver cancer tissue and enhanced SMMC7721 cell tumorigenesis in vivo and vitro.
  • BACKGROUND/AIMS: We screened a novel gene MLC1 in human liver cancer tissue by differential display, and its cDNA full-length is 1600bp.
  • The purpose of this study is to find expression of MLC1 gene in human liver cancer tissue and the affect to SMMC7721 cell tumorigenesis in vivo and vitro.
  • METHODOLOGY: 250 cases of primary HCC tissue samples were studied for MLC1 mRNA and protein expression using RT-PCR, western blot, immunohistochemistry, MLC1 stable transfection into SMMC771, and SMMC7721 cells growth curve was analyzed by MTT method and SMMC7721 cells tumorigenesis in vivo.
  • CONCLUSIONS: MLC1 gene showed up-regulation expression at both the mRNA and protein levels in HCC tissues and that MLC1 plays an important role in the growth of hepatoma cell SMMC7721 in vitro and vivo.
  • [MeSH-major] Carcinoma, Hepatocellular / etiology. Carcinoma, Hepatocellular / metabolism. Liver Neoplasms / etiology. Liver Neoplasms / metabolism. Membrane Proteins / metabolism
  • [MeSH-minor] Adult. Animals. Cell Culture Techniques. Cell Line, Tumor. Female. Humans. Male. Mice. Mice, Inbred BALB C. Middle Aged. RNA, Messenger / metabolism. Transfection. Up-Regulation

  • Genetic Alliance. consumer health - Liver cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16001658.001).
  • [ISSN] 0172-6390
  • [Journal-full-title] Hepato-gastroenterology
  • [ISO-abbreviation] Hepatogastroenterology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / MLC1 protein, human; 0 / Membrane Proteins; 0 / Mlc1 protein, mouse; 0 / RNA, Messenger
  •  go-up   go-down


52. Xia Q, Lu F, Yan HP, Wang HX, Feng X, Zhao Y, Liu BY, Wang J, Li P, Xue Y, Hu MR, Qian L, Guo N, Yang SC, Li MY, Ma YF, Li BA, Zhang XM, Shen BF: Autoantibody profiling of Chinese patients with autoimmune hepatitis using immunoproteomic analysis. J Proteome Res; 2008 May;7(5):1963-70
Genetic Alliance. consumer health - Autoimmune Hepatitis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Sera from 21 patients with AIH and 15 healthy controls were analyzed for the antibody reactivity against the protein antigens of HepG2, a human hepatoma cell line.
  • Immune reactivity to FH was detected in 66.67% of patients with AIH, 19.35% of patients with primary biliary cirrhosis (PBC), 12.31% of patients with chronic hepatitis B (CHB), 6.35% of patients with chronic hepatitis C (CHC), 11.32% of patients with systemic lupus erythematosus (SLE), and 3.57% of normal individuals.
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Amino Acid Sequence. Animals. Autoantigens / immunology. Cell Line, Tumor. Female. Humans. Male. Middle Aged. Molecular Sequence Data

  • Genetic Alliance. consumer health - Hepatitis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18355017.001).
  • [ISSN] 1535-3893
  • [Journal-full-title] Journal of proteome research
  • [ISO-abbreviation] J. Proteome Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Autoantibodies; 0 / Autoantigens; 0 / Proteome
  •  go-up   go-down


53. Onal IK, Turhan N, Oztas E, Arhan M, Akcoren Z, Oguz P, Akdogan M, Onal ED, Kacar S, Kurt M, Sasmaz N: Hepatocellular carcinoma in an adult patient with type IV glycogen storage disease. Acta Gastroenterol Belg; 2009 Jul-Sep;72(3):377-8
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hepatocellular carcinoma in an adult patient with type IV glycogen storage disease.
  • [MeSH-major] Carcinoma, Hepatocellular / complications. Glycogen Storage Disease Type IV / complications. Liver Neoplasms / complications
  • [MeSH-minor] Adult. Female. Humans. Liver / pathology. Young Adult






Advertisement